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I.
Literature Review
INTRODUCTION
In 1937, Congress created the National Cancer Institute, whose
mission has been and continues to be the investigation of the nature
of cancer and its cause and prevention, diagnosis and cure (114).
Within the NCI, the Division of Cancer Treatment (DCT) is responsible
for monitoring the national effort to control cancer through surgery,
radio therapy, immunotherapy, and combined modality therapy (114), in
addition to the development and evaluation of new drugs. It is this
last aspect in which we are most interested.
Research conducted during World War II, particularly on
antibiotics, led to the development of organized research programs in
cancer chemotherapy. Mass screening programs of crude fermentation
products by the pharmaceutical industry resulted in the isolation of
several compounds which were later shown to have antitumor activity
(114).
The Cancer Chemotherapy National Service Center (CCNSC) was
established in 1955 (78), and after several name changes, was merged
with the DCT in 1973 (114). A recommendation was made in late 1957
that the CCNSC should begin a broad screening program of plants. It
was suggested that the Compositae, the Euphorbiaceae, the Labiatae,
the Leguminosae, the Lilliaceae, and the Umbelliferae plant families
be screened first (78). Contracts were let for plant collection,
extraction, and screening of the extracts. The level of screening of
extracts throughout the years has varied according to the budget of
the NCI (78). In addition to plant extracts, synthetic products,
marine animal extracts, and fermentation broths have also been
screened for activity (78). As of 1980, approximately 178,802
microbial cultures have been isolated, and 103,272 plants have been
extracted. In addition, 13,751 extracts from marine products have
been screened, and 0.7% have shown confirmed in vivo activity (27).
A network planning and control technique, the "convergence
technique", has been applied to the natural products screening program
(115). This technique employs decision points throughout the new drug
development process which allow only the most promising compounds at
each step to continue through the screening process, thus allowing
conservation of resources. A prescreen is used to test all compounds.
The activity level is set low in acknowledgment of the fact that no
one tumor cell system can predict the activity of all active compounds
against different tumors (115). The prescreen used over the years has
changed due to back-study correlations between active compounds and
activity against the prescreen. The current prescreen in use is P388
murine macrophage leukemia/lymphoma (105). The P388 prescreen is
effective in predicting activity. It is sensitive to most classes of
clinically effective drugs but sufficiently discriminating (105). In
addition, the P388 cell line has been shown to be exceedingly stable
to changes over time (65).
There is a substantial fallout of active compounds after the
prescreen. Only the most active compounds go on for further testing
to the tumor panel screen. However, some promising compounds are
eliminated due to the problem of obtaining sufficient quantities of
the compound for testing. It is in this area that synthetic organic
chemistry is of value. If a relatively simple synthesis with high
yields can be developed, then promising compounds need not be
eliminated from screening. Also, the total synthesis of known active
compounds would eliminate the need to gather and extract the compounds
from plants or other natural sources, thus saving time and expense
(27).
Synthetic organic chemistry is also of value in preparing analogs
of known anticancer drugs. There are many reasons why analogs are of
importance. Primarily, it is hoped that analogs which show increased
activity and decreased toxicity in comparison with the parent compound
will be developed (112, 27, 13).
The development of analogs is important to different people for
different reasons. For the organic chemist, analogs are useful: for
structure-activity determinations which lead to the rational synthesis
of new and improved drugs for cancer treatment (27); for developing
drugs with improved solubility (13); to separate the components of the
spectrum of action of a drug, such as the toxicity and the
antineoplastic activity, into separate entities (58); to develop drugs
with differences in tissue specificity (58).
For the cancer research scientist, analogs are useful for
determining the mechanisms of action of compounds, which leads to
greater selectivity in choosing drugs for particular diseases (27).
Analogs may: affect a different phase of the cell cycle than the
parent compound (13); exhibit more selective tumor cell killing (13);
show greater retention of activity at various stages of the tumor
cycle( f^ ); or, exhibit more extensive action against nondividing
tumor G cells (13). In addition, analogs may: exhibit increased
entry into tumor cells and/or increased binding to active sites (13);
overcome or delay tumor cell resistance (13); demonstrate therapeutic
synergism when employed in combination with a parent drug or
structurally unrelated compound (13); show greater effectiveness in
preventing metastasis or in the treatment of metastatic tumors (13);
or, show greater activity against oncogenic viruses, viral
transformations, or viral-induced tumors (13).
For the pharmacologist/clinical oncologist, analogs are desired
for the following reasons: a broader spectrum of effectiveness
against experimental tumors (13); diminished limiting or undesirable
acute, chronic, or delayed host toxicity such as myelosuppression,or
gastrointestinal, cardiac, or lung toxicity (13); improved stability
to metabolic destruction or excretion (27); improved duration of
activity and selectivity for a target site (27); greater maintenance
of blood and tissue concentration levels (13); an increase or decrease
in lipid solubility to cross the blood brain barrier (112); more
satisfactory dosage form including greater solubility or greater
stability for oral administration (13); greater effectiveness over a
variety of dosage schedules, and more latitude in the choice of routes
of administration (13).
ANTICANCER AGENTS
Interference with the synthesis or function of nucleic acids, or
with the mitotic process itself is ultimately the mechanism by which
most if not all agents kill cancer cells (70). There are several
classes of anticancer agents, including: hormones; chemically
reactive agents; antimetabolites; DNA complexors; mitotic inhibitors;
and, other agents. As may be expected, some agents fit into more than
one class, and not enough is known about some new agents to enable
their placement into a class. These classes of anticancer agents will
be discussed below. The sheer volume of material already written about
many of these compounds precludes more than a cursory discussion.
HORMONES
In this section, not only will some of the hormones used in
cancer treatment be considered, but also some of the hormone
antagonists.
Unlike the sex hormones which act on a selected group of target
tissues, glucocorticoids act on a wide variety of tissues and organs.
Prednisone, a synthetic steroid, is not active when given orally until
it has been converted in vivo to prednisolone (82). These drugs, like
other glucocorticoids, are cytotoxic to lymphoid tissue, but not to
the bone marrow. Prednisone has been useful in the treatment of acute
lymphoblastic leukemia, and other diseases such as breast cancer,
Hodgkin's disease, and multiple myeloma. Because the drugs affect
many different types of cells, there are a large number of possible
side effects which may include ulcers, cardiovascular and renal
hypertension, and immunosuppression resulting in infections (82).
Because prednisone is not cytotoxic to the bone marrow, it has been
used extensively in combination therapy with other drugs; rarely is
prednisone used as a single anticancer agent (82).
Antiestrogen treatment has become an important strategy in the
management of breast cancer. Approximately 30% of postmenopausal
women with advanced breast cancer respond to endocrine therapy. In
these patients, circulating androgens in the peripheral tissues are
converted to estrogen by the estrogen synthetase enzyme complex,
aromatase (38). By inhibiting this enzyme, tumors are deprived of
estrogen. A new agent, 4- hydroxyandrostenedione , selectively
inhibits aromatase, with fewer side effects than aminoglutethimide.
This latter agent inhibits at an earlier step in steroid biosynthesis,
thereby leading to depletion of corticosteroids, in addition to other
side effects (38).
Tamoxifen is a nonsteroidal antiestrogen used in the treatment of
breast cancer. Not only has tamoxifen shown tumor cell estrogen
receptor blockade (39), but also the inhibition of proliferation of
estrogen receptor-negative cancer cells (42). Research has indicated
that tamoxifen inhibits Ca+2 influx and competes for Ca+2 channel
antagonist binding sites (39). This effect may account for some of the
side effects of tamoxifen, including vasomotor disturbances, nausea,
vomiting, peripheral edema, and headache. These side effects may be
related to the inhibition of Ca+2 flux in smooth muscle (39).
Another antiestrogen
, nafoxidine, has been shown to have
antitumor activity against an ascitic hepatoma. Nafoxidine
competitively inhibited estradiol binding to the tumor cells (55).
CHEMICALLY REACTTVE COMPOUNDS
The chemically reactive compounds are mostly alkylating agents
which act primarily by transferring alkyl groups to cellular
constituents (56). This class includes the nitrogen mustards,
aziridines, methane sulfonates, imidazoletriazenes
, and the
nitrosureas.
Cyclophosphamide is probably one of the best known nitrogen
mustard compounds. The transport form of the drug, 4-
hydroxycyclophosphamide(18), is activated by the hepatic cytochrome
P450 (72), a mixed function oxidase system, to form phosphoramide and
acrolein. Phosphoramide mustard is the alkylating/crosslinking moiety
(18), and acrolein, a highly reactive compound, causes DNA single
strand (ss) breaks and the depletion of glutathione (19).
Melphalan is a nitrogen mustard derivative of L- phenylalanine,
and has been demonstrated to be transported into tumor cells by two
amino acid carrier systems, the large amino acid carrier system and
the sodium-dependent alanine-serine- cysteine transport system (40).
Research results suggest that melphalan is able to be transported
across the blood brain barrier via the large amino acid carrier system
in a facilitated, concentration-dependent manner (40). Melphalan is a
bifunctional alkylating agent capable of producing DNA intrastrand,
and DNA- protein crosslinks (44). However, cell sensitivity to this
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type of drug is determined not only by the number of crosslinks
produced by the drug, but also by the cell's capacity to repair
crosslinks and rate of repair (44). Melphalan activity is
potentiated by the use of buthionine sulfoximine (BSO)(59). BSO is an
agent that can selectively inhibit the rate limiting enzyme in
glutathione (GSH) biosynthesis, thereby depleting tissues of GSH (41).
Glutathione has been shown to have a protective role against cellular
injury (59). This suggests that thiol modulation by BSO or other
agents may be useful as an adjuvant in cancer chemotherapy.
The aziridines are nitrogen mustards which cyclize to aziridinium
ions in vivo. Parent compounds include triethylene melamine (TEM),
and Tris( 1-aziridinyl )phosphorine oxide (TEPA)(70). In newer
compounds, the aziridinyl groups are combined with other reactive
groups, most often quinone structures. Aziridinyl groups are thought
to react with DNA, after opening the ring, in the same way as other
alkylating agents, thus leading to crosslinks (113).
The methane sulfonates are compounds containing a sulfonic acid
ester of nitrogen mustard. Busulfan was used for chronic myeloid
leukemia, but efforts to improve the drug were unsuccessful (70).
More recently, haloethyl sulfonates have been tested.
2-Chloroethyl(methylsulfonyl) methanesulfonate crosslinks DNA after an
initial alkylation at the 6 position of guanine (34). Another
compound, 1 ,5,2,4-dioxadithiepane-2,2,4,4- tetraoxide, may also react
as a bifunctional alkylator. This cyclic compound, however, is
thought to become a negatively charged intermediate after the first
reaction, which may then react preferentially with positively charged
histones which surround the DNA helix. This results in DNA-protein
crosslinks rather than DNA interstrand links (34).
The nitrosureas are both alkylating and carbamoylating agents.
BCNU, 1 , 3-bis ( 2-chl or oe thy 1 )-l-ni trourea
, and CCNU, 1-
(2-chloroethyl )-3-cyclohexyl-l-nitrosurea have been most effective
against Hodgkin's disease, non-Hodgkin's lymphoma, certain brain
tumors, and malignant melanoma. However, bone marrow suppression is
delayed, prolonged, and cumulative (70). The chloroethyl nitrosureas
are unstable compounds that decompose to a variety of reactive species
(35). Two types of alkylation reactions have been demonstrated:
chloroethylations and hydroxyethylations. Chloroethylation of the
guanine 0° position is followed by a slow series of reactions leading
ultimately to interstrand crosslinks. Side reactions such as the
hydroxyethylations could produce unnecessary toxicity, do not
contribute to and may interfere with antitumor activity (35).
However, a majority of human tumor cells and normal cells are capable
of repairing these crosslinks in a stoichiometric, hence depletable,
manner (36). One current strategy used to overcome this is the
pretreatment with the methylating agent N-methyl-N'-
nitro-N-nitrosoguanidine. This causes sensitization to the effects of
chloroethylating agents, but not to other alkylating agents that react
primarily at the N 7 guanine position (36). However, this compound is
highly carcinogenic. Alternatively, s t
r
eptozot oc in , an
N-methyl-N-nitrosurea derivative of glucosamine, is used as a
pretreatment (36). Another strategy is the post treatment with
methylxanthines such as theobromine or caffeine (31). The postulated
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mechanism of action is that the methylxanthines prevent delays in G2
of the cell cycle, thus increasing DNA damage by preventing sufficient
time for repair.
Structure-activity studies have shown that the conjugation of a
cytotoxic moiety to a specific site on a glucosamine molecule can
alter the cytotoxic effects on normal and tumor tissue. The
conjugation of nitrogen mustard to C-2 or C-6 of glucose resulted in
P388 antitumor activity greater than that of nitrogen mustard alone,
with a concomitant reduction in murine bone marrow toxicity (12). Two
compounds with alkylni trosureas conjugated to C-2 of glucose are
streptozotocin and chlorozotocin. These also demonstrated reduced
toxicity with the retention of antitumor activity (2). Conjugation of
a mustard to C-6 of galactose, an isomer of glucose, resulted in a
compound with slightly better activity and lower toxicity than the
corresponding glucose compound (88).
ANTIMETABOLITES
Antimetabolites are compounds that interfere with the synthesis
or function of nucleic acids. Included in this class are: inhibitors
of dihydrofolic reductase; purine analogs; and pyrimidine analogs.
Examples of these are discussed below.
Dihydrofolic Reductase Inhibitors
The best known inhibitors of dihydrofolic reductase are
aminopterin and amethopterin (methotrexate). These 4-amino
derivatives of folic acid are competitive inhibitors that prevent the
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reduction of dihydrofolate to tetrahydrofolate. Tetrahydrofolate is
then converted to a variety of coenzymes that are necessary for
reactions involved in the synthesis of thymidylate, purines,
methionine, and glycine. Thus, inhibition of dihydrofolic reductase
can lead to inhibition of DNA, RNA, and protein synthesis (81).
Methotrexate is useful in the treatment of several human cancers, but
is not effective against many solid tumors, and is limited by toxicity
to normal tissue. In addition, the development of resistance is a
problem (61).
Trimetrexate, (2, 4-diamino-5-methyl-6-[ (3,4 ,5- trimethoxyanilino)
methyl ]quinazoline, is a potent inhibitor of dihydrofolic reductase
(61, 6), although it does not resemble in structure either folic acid
or dihydrofolic acid. Trimetrexate apparently differs from
methotrexate in the mechanism of cell entry and intracellular
metabolism (6). The drug shows activity both in vitro and in vivo:
in vitro, it is active against methotrexate-resistant cells (61); in
vivo, a broader range of activity than methotrexate against murine
tumors is shown (6).
Purine Analog s
Of the purine analogs, 6-mercaptopurine and 6-thioguanine, have
been widely used in chemotherapy. 6-Mercaptopurine is converted by
the purine salvage enzyme Hypoxanthine guanosyl phosphoribosyl
transferase (HGPRT) to 6-mercaptopurine-ribose- phosphate and
6-methy lmercaptopur ine ribonucleotide, both of which act on
amidotransf erase to inhibit de novo purine synthesis (81).
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6-Mercaptopurine-ribose-phosphate also inhibits the conversion of
inosinic acid to adenylic and guanylic acids. Also, 6-mercaptopurine
is incorporated into nucleic acids as 6- thioguanine. Both
mercaptopurine and thioguanine are used primarily to treat acute
leukemias. The principal toxicity is myelosuppression, although liver
toxicity also occurs (81).
3-Deazaguanine, another purine antimetabolite, has been shown to
inhibit the enzymes involved in guanine nucleotide biosynthesis,
including inosine monophosphate (IMP) dehydrogenase and
aminoimidazolecarboxamide ribonucleotide transformylase (79). As with
mercaptopurine, 3-deazaguanine must be activated via HGPRT to at least
the ribonucleotide monophosphate for pharmacological action (79). The
drug decreases L1210 cell viability and DNA and protein synthesis, but
doesn't affect total RNA sythesis. In addition, GTP levels are
lowered to as little as 10% of control values (79). 3-Deazaguanine is
incorporated into nucleic acids: incorporation into DNA causes
irreversible G2-M cell cycle block in CEM cells (69). An analog of
this compound, 6-thio-3-deazaguanine, exhibits even more cytotoxicity
than the parent (69).
A new class of nucleoside analogs, the 2-halo-2'- deoxyadeno-
sines, has recently been reported (48). Although little is yet known
of their metabolic effects, the compounds are relatively resistant to
deamination by adenosine deaminase and so are capable of exerting a
prolonged effect compared with that of the parent compound. The drugs
cause accumulation of cells in S phase, which is more pronounced with
longer exposures and higher concentrations. The loss of cell
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viability is associated with a blockade of some process specifically
occurring at the initiation of S phase (48). In vivo, the optimum
dosage of the 2-chloro compound is lower than that for the 2-bromo
compound against L1210 leukemia (48).
New derivatives of N-hydroxy-N-aminoguanidine have been
synthesized recently, and have been shown to be active against cancer
cells and viral infections through inhibition of ribonucleotide
reductase (110). This enzyme catalyzes the 2'-reduction of
ribonucleoside 5'-diphosphates; thus, inhibition of the enzyme leads
to deoxynucleotide depletion. This in turn causes inhibition of DNA
synthesis. A decrease in RNA synthesis is observed, secondary to the
inhibition of DNA inhibition (110). The isoquinoline derivative of
hydroxyaminoguanidine is the most potent inhibitor of several
compounds prepared. The drug causes an accumulation of cells in
Go/Gl
,
while M phase cells are not replenished (110). This suggests
that the whole of S phase is affected.
Another enzyme, purine nucleoside phosphorylase, is also capable
of being inhibited. This enzyme is essential for purine salvage, as
it catalyzes the phosphoroly s is of guanosine, inosine, and
2
'-deoxyribonucleoside derivatives to purine bases. 8-Amino-9-
benzylguanine is the most potent inhibitor of this enzyme to date
(90). This inhibitor has been used to potentiate the cytotoxicity of
2'-deoxyguanosine for T-cell lymphoproliferative diseases (90), with
much less toxicity than occurs with inhibition of adenosine deaminase
by 2'- deoxycoformycin (57).
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Tiazofurin, 2-a-D-Ribof uranosyl thiazole-4-carboxamide (NSC
286193) is an analog of ribavirin and pyrazofurin (32). This drug is
p ho s phor y 1 a t ed by adenosine kinase and/or a cytoplasmic
5'-nucleotidase (32) to form TAD, an analog of NAD (45). An active
inhibitor of IMP dehydrogenase (87, 45, 32), the drug causes depletion
of cellular guanine pools. An accumulation of IMP results, which, in
turn, inhibits HGPRT (87). While the single agent effectiveness of
tiazofurin has not been established, the drug shows good therapeutic
synergism (45). Another possible use is in sequential chemotherapy:
tiazofurin, followed by 3—deazaguanosine or other guanine analogs
(87).
Finally, neplanocin A is an antibiotic produced by the
actinomycete Ampullariella regularis A11079. An analog of adenosine,
the ribose moiety of neplanocin contains a cyclopentane, which may
cause the compound to be a poor substrate for ribonucleotide reductase
(50). Neplanocin may be activated by adenosine kinase, which would
make neplanocin unique, as there are currently no major antitumor
drugs available that are activated by this enzyme (50). Neplanocin A
selectively inhibits RNA synthesis.
Pyrimidine Analog s
The best known pyrimidine analog is 5-f luorouracil . As with the
purines, this drug must be converted to a nucleotide before it is
cytotoxic. Fluorodeoxyuridylic acid, the active compound, covalently
binds to the active site of thymidylate synthetase in an irreversible
inactivation reaction (81). The drug is more toxic to proliferating
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than to nonproliferating cells, but is effective against several types
of solid tumors. Clinical toxicity is more pronounced in
proliferating tissues, such as the gastrointestinal tract and bone
marrow (81). Use of (E)-5-(2- bromovinyl) uracil increases the potency
of 5-fluorouracil by decreasing its degradation, as the bromovinyl
compound inhibits dihydrothymine dehydrogenase (23).
Cytosine arabinoside, ara-C, is a cytidine analog in which the
hydroxyl group on C-2 of the furanose is reversed, thus allowing the
drug to behave as a 2'-deoxycytidine analog (81). The drug, after
activation, inhibits DNA synthesis, but not RNA or protein synthesis,
through inhibition of DNA polymerases (81). The drug is very poorly
absorbed upon oral administration, and is very rapidly cleared from
the bloodstream. Ara-C is a potent myelosuppressive and is used
primarily to treat myelogenous leukemia. It is not active against
solid tumors (81).
Azacytidine is an analog that has a nitrogen substituted for C-5
of the pyrimidine ring (81). The drug must be incorporated into RNA
in order to inhibit protein synthesis. Azacytidine interferes with
processing of ribosomal RNA. Reduced production of pyrimidine
nucleotides, as a result of inhibition of orotidylate decarboxylase,
may contribute to decreased nucleic acid synthesis (81). The drug is
more effective against proliferating cells, and is used primarily to
treat acute myelogenous leukemia. The deoxy analog of azacytidine is
currently in clinical trials (104). After conversion to a nucleotide
by deoxycytidine kinase, the drug is incorporated into DNA, where it
inhibits DNA methylase. The resulting hypomethylation of DNA has been
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associated with activation of gene expression and induction of cell
differentiation (104). The mechanism of cytotoxicity of the drug
associated with DNA damage may be due to the instability of the drug
incorporated into DNA (104).
Ara-AC is an analog of both Ara-C and azacytidine, combining the
arabinofuranosyl moiety of ara-C with the triazine base moiety of
azacytidine (20). The drug closely resembles ara-C in activity, and
exhibits antitumor activity in a wide variety of tumors, including
three human tumor xenografts. The drug also shows minimal
cytotoxicity to normal murine bone marrow progenitor cells (20).
Cyclopentenyl cytosine has recently been shown to be a potent
inhibitor of replication of KB, L1210, and HT-29 human colon carcinoma
cells. In addition, the drug induces differentiation of human
promyelocytic leukemia cells at concentrations as low as 0.1 uM (71).
Marked reductions in intracellular CTP concentrations suggest that
inhibition of CTP synthesis is a major mechanism of action. The drug
is neither cleaved by uridine phosphorylase nor deaminated by a
deaminase, which suggests that a prolonged duration of action is
possible (71).
Finally, a new agent, 6-f luoro-2-(2'-f luoro-1 , 1 '-biphenyl-4-
yl)-3-methyl-4-quinolinecarboxylic acid sodium salt, has been shown to
inhibit de novo pyrimidine nucleotide biosynthesis (15). The water
soluble compound inhibits dihydroorotate dehydrogenase, the fourth
enzyme in pyrimidine biosynthesis leading to UMP. The drug causes
depletion of pyrimidine nucleotides, with cell death most likely due
to inability to synthesize RNA and/or DNA (15). This mechanism of
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action is unexpected, as the structure does not resemble known
inhibitors.
DNA COMPLEXORS
Compounds that interact with DNA through binding or intercalation
are classified as DNA complexors. Many are antitumor agents or
antibiotics, and many contain an anthracycline structure. Doxorubicin
(adriamycin) is perhaps the best known example of this class.
Adriamycin and daunomycin are believed to act primarily by
intercalating base pairs of DNA with subsequent inhibition of
DNA-dependent RNA synthesis. These anthracycline drugs are limited by
cumulative cardiotoxicity (56). Upon exposure of drug to tumor cells,
an initial ionic attraction occurs which is followed by insertion of
the hydrophobic region of the drug into the phospholipid region of the
cell membrane (11). An increase in membrane fluidity results.
Doxorubicin accumulates in the nucleus to a concentration of about one
drug molecule per nine base pairs of DNA. NMR studies demonstrate
that rings B and C are stacked with the base pairs, while ring D is
not; the sugar residue lies in the minor groove of the DNA. Many
effects have been noted as being due to either the DNA damage or the
changes in the membrane fluidity (11).
Over 500 analogs or derivatives of doxorubicin have been
prepared, but only those which have been reported in the recent
literature will be discussed here.
Aclacinomycin A is the most active of the aklavinone glycosides
against L1210 leukemia. It is orally absorbed, less cardiotoxic,
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nonmutagenic
, and does not cause alopecia, all of which are
improvements over doxorubicin (11). The drug binds to DNA, leading to
an accumulation of cells in the G2 and M phases. Interestingly, RNA
synthesis is preferentially inhibited by aclacinomycin (11).
Nogalomycin is a polyhydroxy anthraquinone (68) that inhibits
nucleolar RNA synthesis more than chromosomal RNA synthesis (11).
This compound has not been utilized, however, due to its excessive
toxicity in animals. 7-0-Methylnogarol (menogaril), a semisynthetic
anthracycline derived from nogalomycin, is the most promising of
several analogs (24). Unlike doxorubicin, menogaril is a weak
inhibitor of DNA and RNA synthesis and causes no inhibition of RNA
polymerase even at highly lethal concentrations (24,25). Menogaril
binds weakly to DNA, compared to doxorubicin, yet is still cytotoxic.
Menogaril accumulates in the cytoplasm (25). There is a
dose-dependent inhibition of progression through S phase with a
complete block in the G2 + M phase (1,25). Cell cytotoxicity studies
indicate that menogaril is most lethal in early Gl , S, and G2, while
cells in late Gl are much less sensitive (25).
A trifluoroacetyl substitution on the amino group of the sugar
residue converts to the doxorubicin analog AD-32. This compound has
been extensively studied. AD-32 is a non- intercalating drug that is
less cardiotoxic than doxorubicin. The drug inhibits nucleic acid
synthesis, but it has been suggested that this is due to the
inhibition of thymidine uptake by the cell (11,77). It is not very
soluble; however, AD-143 is a more soluble analog of AD-32. AD-143
selectively inhibits eukaryotic RNA polymerases I and II at lower
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concentrations than those necessary to effect similar inhibition of
a-DNA polymerase (77).
Cyclic derivatives at the amino group of doxorubicin have
equivalent or greater potency as cytotoxic agents. One such compound,
3
'-deamino-3'-(3-cyano-4-morpholinyl )doxorubicin, is 600 times more
potent than doxorubicin towards P388 tumors in mice (11). This agent
does not produce cardiotoxicity at therapeutically efficacious doses,
and there is no cross resistance to doxorubicin (109).
Structure-activity studies indicate that the morpholinyl moiety, but
not the cyano group, is important in the inhibition of total RNA
synthesis. Also, the morphol inyl-ring containing compounds are
markedly more lipophilic than doxorubicin, resulting in increased
cellular transport (96).
Other analogs of interest include epirubicin, esorubicin, and
idarubicin. Epirubicin is the A'-epimer of doxorubicin, and has equal
activity but less cardiotoxicity than the parent compound (11,77).
Esorubicin, the 4-deoxy analog, is also less cardiotoxic, but has
reduced DNA-binding properties (11), and about twice the
myelosuppression observed with doxorubicin (84). Idarubicin,
A-demethoxydaunorubicin, is more potent, less cardiotoxic, and shows
equivalent DNA binding as the parent compound. In addition, the drug
is orally active (11).
One possible technique used to enhance the cytotoxicity of
doxorubicin and esorubicin is the use of amiodarone. Amiodarone is an
effective anthracycline efflux blocker which acts to prolong the
accumulation of doxorubicin inside the cell, thus helping to overcome
20
resistance (14). The drug is an iodinated benzofurane derivative that
is relatively nontoxic. An antiarrhythmic compound, amiodarone has
been used in Europe for over 15 years in the treatment of angina
pectoris and ventricular arrhythmia (14).
Another compound, hemin, has been shown to preferentially protect
hematopoietic cells from adriamycin induced cytotoxicity (101). This
could be useful for protecting bone marrow cells during anthracycline
treatment of non—hematopoietic malignancies.
Other drugs which complex with DNA cause strand scission.
Bleomycin is probably the best example. DNA strand scission is a
major mechanism of action of the bleomycins, and this action is
enhanced by free—radical—producing systems such as sulfhydryl
compounds or other oxidizing or reducing agents (13). Strand scission
leads to the formation of nucleoside-derived base N- propenals, of
which the thymine and adenine propenals are found to be highly
cytotoxic to a variety of tumor cells in culture (72). Bleomycins
inhibit cell growth during the G2 phase near the S-G2 boundary (72).
Bleomycin is nonmyelosuppressive (56); however, the acute toxicities
associated with the drug are dermatitis and allergy, and the
dose-limiting chronic toxicity is pulmonary fibrosis (13).
Structure-activity test results indicate that the length of the
terminal amine is of significance: although not involved in strand
scission, the terminal amine may be involved in drug penetration into
cells (13).
Other drugs cause strand scission through an effect on the
enzymes DNA topoisomerase I or II. Topoisomerase I modifies DNA
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tertiary structure and is regarded as critical to DNA replication and
gene expression. It has been shown to be inhibited by camptothecin,
in vitro. Topoisomerase II, however, is not effected (47).
Camptothecin, an alkaloid from Camptotheca accuminata
r is a potent
cytoxic agent active against a number of experimental murine neoplasms
(33). The analog, 10- hydroxycamptothecin, has been reported to have
significant clinical antitumor activity in China (9). The biochemical
effects reported include DNA strand scission, and inhibition of DNA
and RNA biosynthesis (46).
Topoisomerase II reversibly cuts double stranded DNA and becomes
covalently linked to the 5' termini at the break site via
phosphotyrosyl bonds. Several drugs stabilize this DNA-enzyme
complex, resulting in increased DNA scission and concomitant
inhibition of the rejoining reaction (97).
One drug which appears to exert its cytotoxic effects by
inhibition of topoisomerase II is VP-16 (etoposide) (62). The
compound is a semisynthetic epipodophyllotoxin that exhibits cell
cycle phase specific cytotoxicity and enhanced effectiveness with
increasing duration of drug exposure. The drug delays cell transit
through S phase and produces cell cycle arrest in the late S-early G2
phase, but is most effective when cells are in S or G2 phase (93). It
has been proven effective against several human malignancies (93).
Other work has shown that putrescine inhibits VP-16-induced single
strand breaks and associated cytotoxic effects, while dif luoromethyl-
ornithine (DFMO), which depletes intracellular putrescine and
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partially reduces intracellular spermidine (64), acts to produce
synergistic cytotoxic effects when combined with VP-16 (26).
Amsacrine, a 9-anil ino-acridine compound, is active against
leukemia and lymphoma, but its activity in solid tumors is
insufficient to warrant further trials. Amsacrine binds to DNA by
intercalation and causes single strand and double strand DNA breaks by
effecting DNA topoisomerase II (100). CI-921 is a 4- (N-methyl-
carboxamide)-5-methyl derivative of amsacrine. The compound is as
potent as amsacrine against murine leukemia, but significantly more
potent against several murine and human lung, colon, breast, and
melanoma cell lines, and against Lewis lung carcinoma, B16 melanoma,
colon 38, and MX-1 axenografts in vivo (100). Similar to VP-16,
CI-921 slows the transit of cells through S phase, with an eventual
accumulation in G2. At subcytostatic concentrations, cell transit is
slowed through late S-G2 phases(lOO).
Nafidimide, a benzisoquinolinedione compound, is currently in
Phase I clinical trials. It, too, produces single strand and double
strand DNA breaks and DNA-protein crosslinks through effects on
topoisomerase II (4).
Two antibiotics from Streptomyces strains, auromomycin and
neocarzinostatin, also cause DNA strand scission, but direct
involvement with topoisomerases I or II has not yet been shown.
Auromomycin is a two component molecule consisting of a fluorescent
chromophore and a low molecular weight apoprotein (85). Similarly,
neocarzinostatin is made up of an acidic single chain polypeptide and
a nonprotein chromophore (76). In both cases, the chromophore is
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responsible for the DNA damaging activity, antitumor activity, and
cytotoxic activity of the compound (85,76).
MITOTIC INHIBITORS
There are several compounds isolated from natural products which
inhibit mitosis in one manner or another and so have been of value in
cancer chemotherapy.
The Vinca alkaloids, vinblastine, vincristine, vinleurosine, and
vinrosidine, are derived from the white flowered periwinkle Vinca
rosea (68). These compounds cause arrest of mitosis in metaphase
through interference with the mitotic spindle. Vinblastine and
vincristine are also known to restrict the synthesis of transfer RNA
(68). The Vinca alkaloids inhibit microtubule assembly and induce
tubulin oligomer formation (7). Vinblastine inhibits
tubul in-dependent GTP hydrolysis (7). However, neurotoxicity limits
the use of vincristine, while leukopenia limits vinblastine (56).
Colchicine, from the autumn crocus, also interferes with spindle
proteins (68). Colchicine stimulates tubul in-dependent GTP hydrolysis
even as it inhibits the microtubule assembly reaction associated with
GTP breakdown (7).
The ansamacrolide maytansine is derived from the East African
shrub Maytenus ovatus
,
and has a macrocyclic lactam ring with a
bridged aromatic moiety in its structure (102). Maytansine inhibits
mitosis in a manner similar to the Vinca alkaloids; however, it has
shown disappointing results in clinical trials (102).
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Taxol is a novel diterpenoid originally isolated from the stem
bark of the western yew Taxus brevifola (108). The compound is a
taxane derivative containing a rare oxetan ring in its structure, and
is the first compound of this type to show activity against B16
melanoma, LI 210 and P388 leukemias, as well as the human MX-1 mammary
tumor, CX-1 colon, and LX-1 lung tumor xenografts (111). Taxol
promotes microtubule assembly by decreasing the critical concentration
of tubulin necessary for microtubule assembly (111). In fibroblasts
and other proliferating cell systems, abnormal bundles of microtubules
form throughout the cytoplasm, and binding of taxol to the
microtubules occurs. Taxol blocks cells in the G2 and M stages of the
cell cycle (111).
A new lactone antibiotic, rhizoxin, is a 16-membered macrolide
isolated from the plant pathogenic fungus Rhizopus chinensis . which
causes rice seedling blight (102). Rhizoxin inhibits mitosis in the
same manner as the Vinca alkaloids, and is effective against
vincristine- and adriamycin-resistant tumor cells in vitro and in vivo
(102).
Synthetic antimitotic agents have also been prepared.
Derivatives of 5 , 6-Diphenylpyridazin-3-one cause rises in the mitotic
index which correlates with the cytotoxicity of the drugs (7). Active
derivatives stimulate tubul in-dependent GTP hydrolysis and either
inhibit tubulin polymerization or induce tubulin oligomer formation,
depending on the reaction conditions. The drugs do not interfere with
binding of labelled colchicine, vinblastine, maytansine, or GTP, which
suggests that a different binding site is involved. Virtually all of
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the active compounds have a nitrile at position 4 of the pyridazinone
ring. Most also have substituents of varying structure at position 2,
but no clear structure-function pattern is yet apparent (7).
OTHER AGENTS
There are several cancer drugs that can not yet be put in one of
the other classes due to lack of knowledge of their mechanisms of
action. In addition, there are new agents derived from natural
products which have not yet been studied extensively.
The cis-platinum compounds have been used with some success to
treat cancer. Cis-diamminedichloroplat inum(II ) (CDDP) entered
clinical trials in 1972. The drug kills cells in all stages of the
cell cycle through a persistent inhibition of DNA synthesis (81). The
drug binds to guanine at 0-6 and N-7 preferentially, but also to
adenine and cytosine. The major dose limiting effect is
nephrotoxicity. Other effects include myelosuppression and hearing
loss (81). CDDP has also shown synergy with a number of other
commonly used agents, including nucleosides and analogs. Use of
thymidine with CDDP against human colon carcinoma cells results in a
2-log increase in cell killing (89).
An important second generation drug is d ichlor o ( 1 , 2-
diaminocyclohexane)platinum(II); however, it is virtually insoluble in
water (43). Water soluble compounds are prepared by substituting an
organic anionic leaving group, an iminodiacetate, for the chloride
ions. These drugs show good antitumor activity, no in vitro cross
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resistance to CDDP, and little or no nephrotoxicity. In addition,
they are easily synthesized with a high overall yield (43).
Gold complexes have also shown antitumor activity. Gold(I)
phosphine complexes are cytotoxic to P388, B16 melanoma, and mammary
adenocarcinoma in vivo (8). The compounds inhibit DNA, RNA, and
protein synthesis within 30 minutes exposure to the drug. This
activity may be due to improved delivery of the cytotoxic ligand to
the target (94).
A group of bis-dioxopiperazines were developed at the Imperial
Cancer Research Fund Laboratory. These analogs of EDTA are
synthesized with the rationale that they might be activated after
entry into the cell (81). ICRF 159 is water insoluble, but its ( + )
enantiomer ICRF 187 is more soluble. Use of ICRF 187 with doxorubicin
has shown synergistic activity (107) which was dose and schedule
dependent. It is possible that ICRF 187 chelates intracellular
cations which may modulate the effects of doxorubicin (107).
There are several new natural products which have shown
anticancer activity. Spergualin is an antibiotic isolated from
cultures of Bacillus, laterosporus
. The 15-deoxy analog had similar
activity in vivo against L1210 leukemia, but was effective at lower
doses (80). The mechanisms of action have not yet been defined, but
it is known that the effects of spergualin depends on the amine
oxidase concentration in the medium (60). Metabolic activation of
deoxyspergualin is required for activity. Infusions of the compound
in dogs causes a toxic cystitis typical of aldehydes (10).
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Illudins are low molecular weight products isolated from certain
mushrooms (3). They were screened against rodent tumor models and
found to have only a narrow index of activity. They have now been
shown to be potent in vitro agents against human tumor cells resistant
to other known anticancer drugs, and may be preferentially active
against leukemias (54). On a molar basis, illudin S is as toxic to
CEM, 8392, and HL-60 cells as the plant toxin ricin. Preferential
inhibition of tritiated thymidine incorporation and arrest in Gl phase
suggests that the compound inhibits DNA sythesis (54).
Agroclavine, an 8-methyl-ergoline type clavine alkaloid, is
produced by fungi of the genera Claviceps . Penicil lium t and
Aspergillus
,
and by certain species of the dicotyledon family
Convolvulaceae (37). It interacts, like the lysergic acid amines,
with dopamine and serotonin receptors, and with - adrenergic
receptors with lower affinity. Agroclavine has antibiotic activity
against some bacteria, and cytostatic activity in the L5178Y murine
lymphoma (37). Its in vitro activity is 10-fold higher for lymphomas
than for normal splenocytes. The derivative, 1-propyl agroclavine,
inhibits thymidine incorporation into DNA, but this is not due to a
direct effect on DNA polymerase a or 8 (29).
L— Canavanine
,
2—amino—4-(guanidinooxy )butyr ic acid, is a
nonprotein amino acid synthesized by many leguminous plants. An
arginine analog, the compound behaves as an antimetabolite (99).
Arginyl-tRNA synthetases are unable to discriminate between canavanine
and arginine, thus leading to structural and functional protein
aberrations. The compound prolongs the life of mice implanted with
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L1210, and produces a significant growth inhibition of solid colon
tumors in rats (99).
Metastatic cancer has always been difficult to treat. Recently,
it was found that the extent of maturation of oligosaccharide subunits
of tumor cell glycoproteins appears to correlate with the malignant
potential. This suggests that modification of the oligosaccharide
structures on tumor cells may alter the metastatic capacity.
Treatment of tumor cells with tunicamycin, swainsonine, or
castanospermine causes a substantial impairment of colonization
potential such that experimental metastasis is blocked (49).
Tunicamycin inhibits the synthesis of an intermediate in the
glycosylat ion process, N- ace ty 1 gl ucosaminylpyrophosphatyl-
polyisoprenol (98). Swainsonine inhibits a-mannosidase II in the
Golgi (30), and castanospermine inhibits glucosidase I (86).
Tunicamycin causes defects in cell adhesion, while the other two do
not. This suggests that 1) complete maturation of oligosaccharide
chains is necessary, and that 2) carbohydrate modifications affect
metastasis in at least two different ways (49).
Certain agents, including a number of low molecular weight planar
compounds, can induce differentiation of malignant cells. Tumor cells
that have differentiated lose their ability to proliferate, to grow in
vitro, and to propagate when transplanted into animals. The rationale
behind this technique includes prevention of the onset of malignancies
in high risk patients, or the conversion of an existing tumor into a
more benign neoplasm with a concomitant loss of growth, invasive, and
metastatic properties (95). HMBA, hexamethylene bisacetamide (NSC
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95580), a compound related to N-methylformamide and DMSO, is the most
potent inducer of differentiation yet defined in this group of
compounds (28), but its utility is questionable due to its lack of in
vivo activity (16).
Photosensitizers have also received attention of late as possible
cancer treatment agents. Hematoporphyrins exhibit selective retention
in tumor cells. After i.v. administration of labelled hematoporphyrin
derivative, there is a gradual accumulation of radioactivity into
tumor tissue (75). Singlet oxygen has been identified as the
cytotoxic agent that is probably responsible for the photodynamic
destruction of malignant cells exposed to light of the appropriate
wavelength and intensity.
Merocyanine dyes have been used as bioelectric membrane probes
(5). Merocyanine-540 selectively stains leukemic cells and some
immature hematopoietic cells (103). Either the electrical properties
or the lipid composition of neoplastic cell membranes allow MC-540 to
preferentially penetrate the membrane. Increased uptake of
membrane-bound merocyanine-540 occurs upon light exposure, which leads
to dye excitation resulting in cell damage and death. How useful
these photosensitizers are, in vivo, remains to be determined.
OVERCOMING DRUG RESISTANCE
Drug resistance by tumor cells is a problem which limits the use
of many anticancer agents. Ways to overcome resistance have also
received attention by researchers. There are several kinds of drugs
that overcome resistance by inhibiting drug efflux (63): calcium
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channel blockers like verapamil; phenothiazine calmodulin inhibitors
like thioridazine, trifluoperazine, and chlorpromazine; liposomotropic
amines like chloroquine and propanolol; and some isoprenoids like
SDB-ethylenediamine and N- (P-methylbenzyl )decaprenylamine. All of
these agents are cationic and amphipathic, and can interact with polar
lipids, especially phospha
t
idy 1 ser ine (63). Binding to
phosphatidylserine can perturb membrane function. Cepharanthine, a
bisbenzylisoquinoline alkaloid, is extracted from a menispermaceous
pl an t, Stephania cepharantha Hayata. It too is cationic and
amphipathic, and is found to decrease fluidity of various biological
membranes (74), thus increasing drug accumulation through inhibition
of drug efflux (91).
TARGETING OF DRUGS
Efforts have been made to target antitumor drugs in an attempt to
reduce toxicity towards normal cells. One attempt involves the
conjugating of a cytotoxic drug to Low-Density- Lipoprotein (LDL)
particles (66). An LDL particle contains about 1500 cholesteryl ester
molecules surrounded by a polar shell containing apoprotein B. Human
cells have receptors for apoprotein B on the surface. After binding,
the LDL is internalized and degraded in lysosomes, resulting in a
release of cholesterol and amino acids. Freshly isolated human
leukemic cells and certain cancer cells in culture have higher LDL
receptor activity than the corresponding normal cells (106). The use
of LDL carriers might avoid some typical carrier problems such as
immunological reactions and rapid plasma clearance (66). One problem
31
misight involve the release of the cytotoxic agent before it can be
destroyed in the lysosome.
Liposomes have evolved from simple drug-encapsulated lipid
carriers to more sophisticated complexes in which lipid composition
(21), size (67,21), and conjugated monoclonal antibodies (17) are all
carefully controlled to ensure target specificity. Liposomes composed
of particular compounds are fusion-competent when exposed to an acidic
environment. Exposure of liposomes to pH 5.0-6.5 (normal pH in
endosomes) will cause them to fuse with adjacent membranes (17). In
addition, liposomes can modify the ability of a drug to partition into
different types of cellular membranes, thus controlling the sites of
drug action (21).
Drugs which severely impair membrane function may have potential
as antitumor agents if toxicities can be limited. Recently,
valinomycin was incorporated into liposomes (21), although it is
likely that the drug intercalated into the bilayers (51). The use of
cholesterol and anionic lipids is also important for reducing
drug-associated toxicities (21).
Synthetic compounds, as varied as they are, demonstrate a variety
of anticancer effects. Some rationally designed compounds, such as
nucleoside analogs, demonstrate activities which are expected on the
basis of their structures. Others exhibit activities different from
what was expected, or show no activity at all. The structures of
other compounds provide no clue as to their mechanisms of action, as
in the case of 6- f luoro-2-(2'-f luoro-1 , 1 '-biphenyl-4-yl)-3-methyl-
4-quinoline carboxylic acid sodium salt (15).
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The synthetic compound, 1-pheny 1-3-pheny lamino-4- ( p-
toluenesulf inyl)trans-l ,5-hexadiene, is an intermediate in the
synthesis of an antibiotic carbapenum (83). Its structure does not
resemble other known anticancer agents; however, the structure of the
proposed intermediate in solution suggests a mechanism of action
similar to the alkylating agents.
In this thesis, the cytotoxicity of the synthetic compound,
1-pheny l-3-phenylamino-4-(p-toluenesul f inyl ) trans-1 , 5-hexadiene
(Sulfoxide 1), was examined both in vitro and in vivo. The mechanism
of action in vitro was determined by synthesis inhibition studies
using radiolabeled precursors. In addition, the toxicity of the
compound for normal cells was determined. Additional studies on the
cytotoxicity of a p-chloro analog, and liposome delivery system of
Sulfoxide 1 were also completed. Results herein suggest that
Sulfoxide 1 is more cytotoxic towards proliferating than
nonproliferating cells, and that this cytotoxicity occurs through
inhibition of DNA and/or RNA synthesis.
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II.
In Vitro Cytotoxic Activity of l-Phenyl-3-phenyl
amino-4-(p-toluenesulfinyl)-trans-l,5-hexadiene
ABSTRACT
A novel anticancer drug, 1-pheny 1-3-pheny lamino-4- ( p-
toluenesulf inyl )-trans-l ,5-hexadiene has been synthesized and found to
have in vitro cytotoxicity against P388 (LD5 = 30 ug/ml ) and L1210
(LD5Q= 29 ug/ml) murine leukemia cells in culture. The LD50 compared
favorably with that for doxorubicin. The compound was more cytotoxic
to P388 tumor cells than to normal mouse splenocytes. The compound
inhibited the uptake of both tritiated thymidine (42% inhibition) and
tritiated uridine (24% inhibition) after 3 hours of incubation when
used at 5 ug/ml. No effect on uptake of tritiated leucine was
observed during this time period. The compound was cytotoxic to
normal mouse splenocytes which had been stimulated to divide by the
mitogen concanavalin A. No effect was found on normal, non-dividing
splenocytes. These results suggest that this novel compound is
cytotoxic to leukemic cells or other rapidly dividing cells through
inhibition of DNA and/or RNA synthesis.
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INTRODUCTION
As part of a continuing study of stereospecif ic addition
reactions of sulf inylallyl anions with ambident electrophiles (1) and
their application in the asymmetric total synthesis of antibiotic
carbapenums (2) and py r r o 1 i z i d i ne alkaloids, 1-phenyl-
3-phenylamino-4-(ptoluenesulf inyl )-trans-l ,5-hexadiene was synthesized
from cinnamylidene aniline (Fig. 1). This sulfoxide undergoes an
elimination reaction in solution to form aniline and a conjugated
triene, which may act as a Michael acceptor (3) of a nucleophile from
DNA, RNA, or protein. The triene may act as a DNA crosslinker similar
to the mitomycins (4).
Preliminary testing of the drug has involved in vitro
cytotoxicity assays against the P388 and L1210 murine cell lines;
comparison of cytotoxicity with those of prednisone and doxorubicin;
DNA, RNA, and protein inhibition assays; time course of DNA and RNA
inhibition studies; and cytotoxicity assays against normal cells
(splenocytes)
.
Results of this work are reported herein.
MATERIALS AND METHODS
Drug s and Chemicals . [methyl-%] thymidine (56 Ci/mmol),
[5,6- 3H] uridine (50 Ci/mmol), and [ 2 , 3 , 4 , 5- 3H]-L-leucine (110
Ci/mmol) were purchased from ICN Radiochemicals, Irvine, CA.
Prednisone, doxorubicin, sodium bicarbonate, and Con A (Type IV) were
obtained from Sigma, St. Louis, MO. RPMI 1640 powdered media and
penicillin-streptomycin solution (10,000 units/ml and 10,000 jjg/ml)
were purchased from KC Biologicals, Lenexa, KS. FCS was obtained from
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Hazleton-Dutchland, Denver, PA. DMSO was from Burdick & Jackson
Laboratories. Phosphate buffered saline, (PBS), pH 7.2, contained 137
mM NaCl
,
6mM Na2HPC>4, and 1.5 mM KH2PO4 and was sterilized by
autoclaving. Cinnamylidene aniline, cinnamylidene p-chloro aniline,
Sulfoxide 1, and the p-chloro analog of Sulfoxide 1 were prepared by
DHH as described in (1).
Animals. Balb/c mice were originally obtained from The Jackson
Laboratory, Bar Harbor, ME, and propagated in-house. Mice were housed
in plastic cages under standard laboratory conditions with free access
to food and water.
Ce_U Culture
. Cell lines were originally obtained from the
American Type Culture Collection, Rockville, MD, and propagated in
house. P388 and L1210 cell cultures were maintained in RPMI 1640
media, pH 7.2, supplemented with 10% heat-inactivated FCS, 2 g/1
sodium bicarbonate, 100 IU/ml penicillin, 100 ug/ml streptomycin.
Cultures were incubated at 37 °C in a humidified atmosphere of 5%
C02/95% air. Cells were passed regularly into fresh media at 3 day
intervals, and only actively growing cultures in the logarithmic stage
of growth were used in experiments. Cell number and viability were
determined by hemocytometer counting using trypan blue dye exclusion.
Cytotoxicity Assays . P388 or L1210 cells (5 x 10 6 cells/well)
were cultured in RPMI 1640 with concentrations of 20, 24, 32, 40, or
48 ug/ml of Sulfoxide 1 in a final volume of 2 ml/well in 24 well
plates for LD50 determinations. After 24 and 48 hours, samples were
withdrawn for cell number and viability determinations. Cells were
also cultured with prednisone dissolved in 6% DMSO and with
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doxorubicin dissolved in PBS at varying concentrations for LD50
determination.
In another experiment, P388 or L1210 cells (7.5 x 10 5 cells/ml)
were cultured in RPMI 1640 with 10, 20, 25, 30, or 40 ug/ml of
Sulfoxide 1 or the p-chloro analog of Sulfoxide 1 for LD50
determinations after 24 hours as above.
Incorporation of Labeled Precursors . P388 or L1210 cells (1.5 x
10 5 cells) were cultured in RPMI 1640 with 1, 2, 4, or 6 ug of
Sulfoxide 1 in a final volume of 200 ul in each of two 96 well plates.
One plate was used for counting cell number and viability at 3 and 6
hours after assay set up. The other plate was used for pulse
labelling of cells for 3 hours with 1 uCi of either
[methyl-3H]-thymidine, [5,6-3H]-uridine, or [2,3,4,5-%]- L-leucine,
after which the cells were harvested onto Titertek GFA filters (Flow
Laboratories, Rockville, MD) using a suction filtration/ water wash
Titertek cell harvester. For the protein assay, the cells were
precipitated with TCA (10% TCA final concentration) onto Whatman 3 mm
chromatography paper and washed with 95% ethanol
. The filters were
allowed to dry before counting in a Beckman LS 3801 liquid
scintillation counter. Results were calculated for comparison as
cpm/10^ viable cells.
Time Course of DNA and RNA Inhibition . L1210 cells (1.5 x 10 5
cells/well were plated into 96 well plates for a simultaneous DNA/RNA
assay. At 30 minute intervals between and 6 hours, 6 ug of
Sulfoxide 1 in 6 ul of DMSO, or 6 ul of DMSO alone was added to the
appropriate wells. The cells were pulse labelled with either
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[methyl-3H] thymidine or [ 5, 6-3H] uridine for the final hour of drug
exposure. At time 0, cells were harvested on the cell harvester,
dried, and counted on the scintillation counter as previously
described. Results were plotted as percent of control cpm vs. time
(Figure 2).
Effect on Normal Cells . Cytotoxicity of Sulfoxide 1 for normal
cells was determined using splenocytes from the spleens of 6-8 week
old BALB/c mice of both sexes. The splenocytes were cultured for 24
hours at 37 °C in a humidified atmosphere of 5% CC>2/95% air in flasks
containing RPMI 1640 supplemented with 10% FCS. Half of the
splenocytes were in separate flasks containing Con A at a
concentration of 20 ug/ml. After 24 hours, the splenocytes were
pelleted, resuspended, and counted to ensure that the same number of
viable cells, 3 x 10 5cells/well , were plated. Three different volumes,
1,4, or 8 ul of Sulfoxide 1 dissolved in DMSO at 1 Ug/ml, or the
corresponding volume of solvent alone were added to the wells with
media to a final volume of 200 ul. P388 cells were treated in the
same manner as a control. Cell number and viability were determined
after 24 hours as discussed above.
In another experiment, spleen cells and P388 cells were treated
in the same manner as above, except that cells were pulse labeled for
the final three hours with 1 uCi of [methyl-3H]- thymidine before
harvesting and counting on the liquid scintillation counter as above.
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RESULTS
Properties. l-phenyl-3-phenylamino-4-(p-toluenesulf inyl )-
trans-l,5-hexadiene (Figure 1) is a white powder, soluble in ethanol
and DMSO, but insoluble in aqueous solution. Sulfoxide 1, both powder
and in solution, is stored at °C . The powder is stable
indefinitely. Upon prolonged storage or under acidic conditions,
solutions will turn yellow, indicating the presence of the triene
rearrangement product.
Cytotoxicity of Sulfoxide 1
. Sulfoxide 1 is cytotoxic to both
L1210 and P388 cells (Table 1). Diminished viability is observed for
both cell lines at 3 hours at the highest concentration of Sulfoxide 1
used. At 6 hours, there is a slight decrease in viability for both
cell lines at all concentrations of Sulfoxide 1 used, with the biggest
decrease occurring with the L1210 cells (a decrease from 79.37% to
65.90% viability at 42.5 ug/ml Sulfoxide 1). By 24 hours, half or
more of all cells cultured with Sulfoxide 1 are dead, and at the
highest concentration used, both P388 and L1210 cells were only =20%
viable. From the LD50 , it appears that P388 and L1210 cells are
approximately equal in sensitivity to Sulfoxide 1.
Comparison of Sulfoxide 1 Cytot oxicity to that of Prednisone and
Doxorubicin
.
Sulfoxide 1 compares favorably with prednisone and
doxorubicin with regard to cytoxicity towards tumor cells in culture
(Table 2). Doxorubicin exhibited a nonlinear, biphasic curve (not
shown) such that after 48 hours, both 12.5 ug/ml and 60 ug/ml produced
50% cell killing. An LD50 could not be determined for doxorubicin at
24 hours. In order to achieve 50% cytotoxicity, a dose of prednisone
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more than 27 times that of Sulfoxide 1 was required. The LD50 of
Sulfoxide 1 for L1210 cells was determined to be 29 ug/ml and the LD50
for P388 cells was 30 Ug/ml.
Cytotoxicity of the p-chloro analog of SulfoviHp
1
. The analog
of Sulfoxide 1 showed cytotoxicity comparable to that of Sulfoxide 1.
The LD50 of the p-chloro analog for L1210 cells was determined to be
68 uM and for P388 cells was 53 uM. The LD50 of the parent compound,
Sulfoxide 1, for L1210 cells was determined to be 41 uM and for P388
cells 38 uM. These results suggest that P388 cells are more sensitive
than L1210 cells to Sulfoxide 1. The addition of a p-chloro group on
the phenylamino moiety does not appear to alter the biological
activity of the compound. Also, solubility in ethanol is slightly
increased, thus making possible a less toxic solvent for drug
delivery.
DNA, RNA, and Protein Svnt-hpg-i q For both P388 and L1210 cells,
uptake of t 3H]thymidine decreased by 42% at 5 ug/ml during the first 3
hours of the assay (Table 3). Decreases of 65% (L1210) and 85% (P388)
were observed at 30 ug/ml Sulfoxide 1 during this same time. The
viabilities for both P388 and L1210 cells were greater than 90% at 5
Ug/ml, while at 30 ug/ml P388 cells were =65% viable and L1210 cells
were =75% viable. However, the results (cpm's) were normalized for
the number of viable cells so that these large decreases in thymidine
uptake are due to the higher concentration of Sulfoxide 1 present.
Further, more modest decreases in thymidine uptake were observed at 6
and 24 hours (24 hour data not shown). Similar results were obtained
using r 3H]uridine for both P388 and L1210 cells. An inhibition of 15%
59
and 24% respectively was observed at 3 hours using 5 ug/ml Sulfoxide
1. There was no inhibition of protein synthesis as shown by uptake of
[
3H]-L-leucine during the first 3 hours of the assay.
Time Course of DNA and RNA Inhibition . It is possible that
Sulfoxide 1 reacts with both DNA and RNA, or, with DNA only, which, in
turn, would cause a decrease in DNA-dependent-RNA synthesis. In order
to better determine the mode of action of Sulfoxide 1, simultaneous
DNA/RNA time course studies were completed. The results in Figure 2
indicate that both DNA and RNA are inhibited most strongly, and to
about the same degree, within the first hour of exposure to Sulfoxide
1. A slight variability of inhibition between separate experiments
was observed, which may be due to the slightly different percentages
of cells in the stages of the growth cycle. DMSO also inhibited the
uptake of labelled nucleotide within the first 1-1.5 hours. This
effect has been previously noted (15). However, even though there is
inhibition due to DMSO, there is enhanced inhibition when Sulfoxide 1
is present. After 1.5 hours, DNA and RNA were inhibited by DMSO to
48.7 and 50.2 percent of control, respectively, while inhibition by
Sulfoxide 1 was to 29.3 and 11.2 percent of control, respectively.
Effects on Normal Cells
. In order to determine whether Sulfoxide
1 was cytotoxic to non-tumor cells, and whether mitotic cells were
re vulnerable to the effects of Sulfoxide 1, spleen cells were
timulated with mitogens. The T cell mitogen Con A was used to
stimulate half of the splenocytes for 24 hours prior to exposure to
Sulfoxide 1 (Table 4). After a further 24 hours, the splenocytes
cultured with and without Con A were =60% viable in the absence of
mo
s
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Sulfoxide 1 and DMSO. A small decrease in viability was observed with
increasing Sulfoxide 1 concentration, such that at 40 ug/ml the
splenocytes were 45% viable. There was very little difference in the
observed viabilities of splenocytes cultured with and without Con A.
It appeared that the mitogen Con A did not have an effect on the
cytotoxicity of Sulfoxide 1 towards the spleen cells, as measured by
trypan blue dye exclusion. It is unlikely that the spleen cells
cultured with Con A were no longer in the process of dividing during
the time of Sulfoxide 1 exposure, since the results of a preliminary
experiment indicated that 48 hours exposure to 20 ug/ml Con A was
optimal (See Chapter 3). The DMSO effect on cell viability was
negligible compared with the effects of Sulfoxide 1.
In Table 5, however, a major difference in the uptake of
tritiated thymidine by cells treated with and without Con A is
apparent. Spleen cells which were not treated with Con A incorporated
similar amounts of tritiated thymidine after exposure to Sulfoxide 1.
Spleen cells treated with Con A, however, were more susceptible to
both DMSO and Sulfoxide 1. At the highest two concentrations used,
the spleen cells exposed to Sulfoxide 1 incorporated only 1.6% and
6.4% as much labelled thymidine, respectively, as the cells exposed to
DMSO. P388 cells were also susceptible to both Sulfoxide 1 and DMSO,
although the cells treated with Sulfoxide 1 incorporated only 34- 42%
as much thymidine as those cells treated with DMSO.
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These results suggest that mitotic cells are more vulnerable to
Sulfoxide 1 than non-mitotic cells, although due to the small number
of counts incorporated by the spleen cells not treated with Con A and
the variation in the counts of the cells exposed to DMSO, this is not
certain.
DISCUSSION
The antibiotic penicillins and cephalosporins are perhaps the best
known examples of natural products which contain in their structures
the beta-lactam ring (6). In these compounds, the beta-lactam ring is
fused with a five- or six-membered sulfur-containing ring. Structural
analogs in which the sulfur has been replaced by a carbon atom are
known as carbapenums, and are several times more biologically active
than the sulfur- containing compound. Sulfoxide 1 is an intermediate
compound in the attempted synthesis of a carbapenum (7).
Among the so-called antitumor antibiotics, the bleomycins, for
example, contain a mono-beta-lac tarn ring in their structures (8). The
effectiveness of the bleomycins occurs through inhibition of DNA
synthesis and/or strand scission (9). Strand scission leads to the
formation of base propenals which may be responsible for many of the
cytotoxic effects of bleomycin unexplainable by DNA damage alone (9).
The cytotoxicity of Sulfoxide 1 for tumor cells was not
unexpected, given that the conjugate addition of nucleophiles and the
triene may occur, similar to the reaction of elephantopin with
cysteine (3). Sulfoxide 1 may also undergo types of reactions similar
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to Mitomycin C, another of the antitumor antibiotics. It has recently
been shown that Mitomycin C crosslinks with DNA (10). The reducing
conditions influence whether mitomycin C reacts as a mono- or
bifunctional DNA alkylating agent. Sulfoxide 1 also has the potential
to react as a mono- or bifunctional alkylating agent due to the
formation of the triene in solution. Mitomycin C is most active in
late Gl- early S phase, but is considered to be cycle nonspecific
(11). In general, alkylating agents are relatively cell cycle and
phase nonspecific, and do not require active cellular replication to
be effective in producing cytotoxicity (12). If Sulfoxide 1 acts as
an alkylating agent, then perhaps more cytotoxicity towards the
normal, non-replicating spleen cells should have been observed.
Doxorubicin, an anthracycline antibiotic, is believed to act
primarily by intercalating between base pairs of DNA with inhibition
of DNA-dependent RNA synthesis (11). Doxorubicin, however, is less
toxic to normal spleen cells than to leukemic spleen cells (13). The
possibility remains that Sulfoxide 1 acts in this manner.
The synthetic compound 1-pheny 1-3-pheny lamino-4-( p-
toluenesulfinyl)-trans-l,5-hexadiene (Sulfoxide 1) has been shown to
be cytotoxic to tumor cells in vitro . The cytotoxicity is observed
within 3 hours of exposure to the drug. After 24 hours exposure to
greater than 40 ug/ml Sulfoxide 1, P388 and L1210 leukemia cells
decrease to 20% viability, and after 48 hours exposure, viability
decreases to less than 10%.
Sulfoxide 1 is not soluble in aqueous solution, necessitating the
use of other solvents. DMSO was chosen because of its low
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cytotoxicity when used in small quantities, and because Sulfoxide 1
showed marked cytotoxicity for tumor cells when dissolved in DMSO.
DMSO is known for its ability to penetrate membranes (14), and may aid
in the uptake of Sulfoxide 1 into the cell through the transient
permeabilization of the cell membrane which thus allows the uptake of
compounds normally excluded by the membrane. This suggests the need
for a liposome or other drug delivery method for in vivo testing
against tumors.
In order to determine the mechanism of cytotoxicity of Sulfoxide
1, its effects on the synthesis of DNA, RNA, and protein were tested.
DNA synthesis was inhibited more than RNA synthesis during the first
three hour time block, while protein synthesis was not inhibited at
all. This suggests that the cytotoxicity of Sulfoxide 1 is due to
inhibition of DNA synthesis. The inhibition of RNA synthesis may be a
direct consequence of this DNA inhibition, or it may be the result of
Sulfoxide 1 reacting directly with the RNA. There is no clear
indication of how Sulfoxide 1 affects protein synthesis after the
initial three hours.
In order to better determine whether Sulfoxide 1 reacts with DNA,
RNA, or both, simultaneous DNA/RNA synthesis inhibition assays were
performed. The results indicate that both DNA and RNA are inhibited
most strongly, and to about the same degree, after one hour of
exposure to Sulfoxide 1. This suggests that Sulfoxide 1 reacts with
both DNA and RNA. The differences in the amount of inhibition of DNA
and RNA after three hours seen in the previous experiment may be due
to the differences in the cell populations of actively growing cells
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on different days. This would also explain the slight variability in
the degree of inhibition after one hour seen in the simultaneous assay
performed on different days. In order to determine if Sulfoxide 1
exhibits phase specificity, or whether Sulfoxide 1 is nonspecific but
is more cytotoxic in a particular phase, studies using synchronized
cells are suggested.
Because Sulfoxide 1 inhibited both DNA and RNA synthesis, it is
probable that protein synthesis is also inhibited, as a consequence of
the DNA and RNA inhibition. A different method for harvesting the
cells from the proteing synthesis inhibition assay may be successful
in detecting this time-delayed inhibition.
The results of testing against spleen cells in Tables 4 and 5
suggest that Sulfoxide 1 may not be as cytotoxic to normal,
non-dividing cells as it is to leukemic cells. The results also
suggest that 1) Sulfoxide 1 may have a cytostatic effect, depending on
the dose, in that the uptake of tritiated thymidine does not correlate
with cell death as measured by trypan blue, and/or that 2) trypan blue
dye exclusion may not be a valid means of comparing viability between
different types of cells due to differences in cell membrane
composition which may allow preferential uptake of the dye.
The preference of Sulfoxide 1 for rapidly dividing cells suggests
that the compound may be toxic to tissues such as the bone marrow and
gastrointestinal tract, which is a common problem with many anticancer
drugs.
In summary, Sulfoxide 1 has been shown to be more cytotoxic to
murine leukemia cells than spleen cells, and this cytotoxicity occurs
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through inhibition of DNA and/or RNA synthesis. Further testing of
Sulfoxide 1 will include toxicity in animal models and in vivo testing
against tumors.
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Table 1. Cytotoxicity of Sulfoxide 1 for P388 and L1210 leukemia
cells. 3
Percent Viability*3
Sulfoxide 1
(ug/ml) 3 hr
P388 cells
93 ± 6 .2
12.5 75 ± 12 .9
35.0 70 ± 9.,7
52.5 60 ± 11. 8
6 hr 24 hr
93 ± 5.6 95 ± 5.8
74 ± 5.6 50 ± 8.7
61 ± 5.3 31 ± 7.6
53 ± 5.0 21 ± 3.0
L1210 cells
93 ± 7.2 94 ± 5.1 97 ± 2.6
12.5 81 ± 7.2 76 ± 5.3 66 ± 12.5
25.0 78 ± 11.2 76 ± 7.0 41 t 6.3
42.5 79 ± 8.2 66 ± 7.6 24 ± 5.0
aP388 and L1210 cells (7.5 x 10 5 cells/ml) were cultured with the
indicated doses of Sulfoxide 1 for 3,6, and 24 hours at 37 °C. Cell
number and viability were determined by hemocytometer counting using
trypan blue dye exclusion.
b Average ± SEM of 4 (P388) and 5 (L1210) experiments.
cCell counts after 24 hr at the highest concentration used we
1.5 x 1(P cells/ml (P388) and 1.8 x 10 5 cells/ml (L1210).
re:
Solvent effects generally caused less than a 10% decrease in
viability after 24 hr at the highest concentration used, and have not
been subtracted from these results.
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Table 2. LD50 Dose Determination. 3
Drug P388 cells/ml LD50 (ug/ml)
Prednisone 7.5 x 10 5 828
Doxorubicin 7.5 x 10^ 12.
5
b
Sulfoxide 1 5.0 x 10 5 30 c
P388 cells were cultured with varying concentrations of
prednisone, doxorubicin, or Sulfoxide 1 for 24 hours at 37 °C. Cell
number and viability were determined as in Table 1.
bLD50 at 48 hours.
CLD50 for L1210 cells (6.1 x 10 5 cells/ml) is 29 ug/ml.
All results were calculated from dose response curves using
concentrations ranging from to 250 ug/ml (doxorubicin), to 850
Ug/ml (prednisone), and to 50 ug/ml (Sulfoxide 1). Results are from
2 or more experiments using 3 well replicates per concentration.
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Table 3
-
Effect of Sulfoxide 1 on DNA.RNA.and Protein Synthesis5
Sulfoxide 1 cpm/10 5 L1210 cellsb cpm/10 5 P388 cell «b
(Ug/ml) 3 hr 6 hr 3 hr 6 hr
DNA Synthesis
68,852 ± 21,234 20,154 ± 3983 78,987 ±17,941 57,697 t 9509
5 39,171 ± 7,860 8,877 ± 1533 45,334 ± 2,267 19,798 ± 1466
10 45,877 ± 13,609 7,608 ± 491 29,587 1 3,261 11,861 ± 842
20 25,341 ± 5,818 5,000 ± 1888 12,892 ± 3,249 7,153 ± 1425
30 23,876 ± 3,672 6,356 * 1868 11,874 ± 580 3,364 ± 801
RNA Synthesis
25,792 ± 3,008 20,861 ± 2380 10,225 ± 1,372 4,839 ± 520
5 19,485 ± 481 15,410 ± 2128 8,682 ± 1,103 3,636 ± 419
10 20,535 ± 2,077 13,575 ± 1908 6,949 ± 336 3,030 ± 287
20 11,488 ± 2,429 8,149 ± 838 6,652 ± 582 3,533 ± 337
30 9,073 ± 649 5,144 ± 411 8,146 ± 1,019 3,385 ± 264
Protein Synthesis
1,146 ± 76 1,605 ± 99
5 1,063 ± 100 1,639 ± 66
10 1,237 ± 195 2,061 ± 212
20 1,225 4 149 2,788 ± 511
30 1,312 ± 188
aP388 or L1210 cells (7.5 x loVml) were cultured with indicated
doses of Sulfoxide 1 for 3 and 6 hours at 37 °C. Cells were pulsed for
3 hours with 1 yCi of either 3H-thymidine , 3H- uridine
, or
H-L-leucine before harvesting. After counting, cpm's were normalized
for the number of viable cells, as determined by cell number and
viability counts from a duplicate plate.
bAverage ± SEM, n = 4
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Table 4. Effect of Sulfoxide 1 on Normal Cells3
Percent Viability **
Volume Experiment 1
Lull Sulfoxide 1 DMSO
Splenocvtes without Con A
52 ± 10
1 57 ± 8 47 ± 9
4 57 ± 8 46 ± 7
8 44 ± 2 12 ± 2
Splenocvtes with Con A
66 ± 4
1 64 ± 5 63 ±10
4 56 ± 6 58 ± 8
8 48 ± 4 37 ± 8
P388 cells
81 ± 2
1 71 ± 5 74 ± 5
4 22 ± 4 75 ± 2
8 13 ± 3 73 ± 4
Experiment 2
Sulfoxide 1 DMSO
61 * A
58 ± 9 50 ± 2
45 ± 7 65 ± 4
43+5 71 ± 8
60 ± 11
56 ± 4 41 ± 5
47 ± 4 68 ± 4
41 ± 5 64 ± 4
97 ± 1
92 * 1 96 ± 1
23 ± 1 93 ± 2
23 ± 1 88 t 4
aSpleen cells (1.5 x 10 6 cells/ml) were cultured with or without
Con A (20 ug/ml) and the indicated doses of Sulfoxide 1 (1 ug/ul in
DMSO) or DMSO at 37 °C. Cell number and viability were determined as
in Table 1.
bAverage ± SEM, n = 4.
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Table 5. Effect of Sulfoxide 1 on Normal Cellsa
cpm'sk
Volume
lull Sulfoxide 1 DMSO
Splenocvtes without Con A
545 ± 52
1 358 ± 32 769 ± 198
4 400 ± 212 181 ± 72
6 378 ± 132 277 ± 177
Splenocvtes with Con A
1
4
6
P388 cells
1
4
6
21,213 ± 2648
23,327 ± 3888 18,126 ± 747
472 ± 114 7,360 ± 665
58 ± 10 3,586 ± 263
25,345 ± 2562
10,430 ± 703 26,890 ± 1746
4,301 ± 195 10,124 ± 809
2,350 ± 312 6,885 ± 176
aSpleen cells (1.5 x 10 6cells/ml) were cultured with or without
Con A (15 ug/ml) and the indicated doses of Sulfoxide 1 (1 ug/ul in
DMSO) or DMSO at 37 °C. Cells were pulsed for 3 hr with 1 uCi of[methyl—3H]-thymidine prior to harvest.
bAverage ± SEM, n = 4.
74
as
Fig. 1. Structure of Sulfoxide 1. Sulfoxide 1 (3) was synthesized
a 1,2-a-adduct from (±)p-tolyl allyl sulfoxide (1) and cinnamylidene
aniline (2). In solution, sulfoxide 1 undergoes an elimination
reaction to produce the triene sulfoxide (4) and aniline.
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Fig. 2. Time Course of DNA and RNA Synthesis Inhibition. L1210 cells
(1.5 x 10 5 cells) were exposed to 6 ug of Sulfoxide 1 in DMSO or 6 ul
of DMSO for varying lengths of time, then pulse labelled for 1 hour
with 1 uCi of either tritiated thymidine or tritiated uridine.
Results are expressed as percentage of control cpm. The upper curves
show the inhibition of DNA (-o-) and RNA (-•-) due to DMSO; the lower
curves show the inhibition of DNA (-o-) and RNA (-•-) due to Sulfoxide
1.
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III.
Further Studies on Sulfoxide 1
INTRODUCTION
In the previous chapter, the cytotoxicity of Sulfoxide 1 for
tumor cells in vitro was shown. Additionally, it was shown that
Sulfoxide 1 inhibits DNA and RNA sythesis in a dose-dependent manner,
and that this inhibition occurs within the first hour of drug
exposure.
To further investigate Sulfoxide l's DNA binding properties and
activity in vivo, additional experiments have been completed. In this
chapter, the results of these additional experiments, as well as the
results of preliminary work, are reported. These include the
solubilization of Sulfoxide 1, the toxicity of Sulfoxide 1 for mice,
the effects of Sulfoxide 1 on tumor-bearing mice, the DNA-binding
ability of Sulfoxide 1 as measured by equilibrium dialysis, the
optimal conditions for Con A stimulation of splenocytes, and a protein
assay on tumor cells. The conclusions from each set of experiments
are discussed at the end of each section.
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Solubilization of Sulfoxide 1
Any new compound must be dissolved in a suitable solvent prior to
testing. Water soluble compounds are preferred for ease of testing
and, later, for clinical administration. However, most organic
compounds are not readily soluble in aqueous solution, necessitating
the use of other solvents which, when diluted in aqueous media, will
maintain the compound in solution. After the efficacy of the compound
has been determined, structural analogs which are designed to increase
water solubility may be prepared. Modifications may include the
addition of more hydrophilic or polar groups to aid in solubility, or
the conjugation of the compound to a water soluble moiety such as a
carbohydrate molecule as in the case of doxorubicin (1).
Attempts were made to dissolve Sulfoxide 1 in different solvents
as detailed below.
Materials and Methods
Reagents, Sulfoxide 1 was prepared by Dr. D. H. Hua. Fatty Acid
Free Bovine Serum Albumin (BSA) was a gift of Dr. R. S. Ochs. DMSO
was from Burdick & Jackson Laboratories. L-a- Phosphatidylcholine
(PC) (100 mg/ml), and L-a-phosphatidyl-L- serine (PS) (10 mg/ml), were
from Sigma. BSA (Fraction V) was from United States Biochemical
Corporation, Cleveland, OH. Phosphate buffered saline (PBS), pH 7.2,
contained: 137 mM NaCl
, 6 mM Na 2HP04 , and 1.5 mM KH2PO4, and was
sterilized by autoclaving.
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Results and Discussion
Sulfoxide 1 was found to be insoluble in both water and PBS, but
was known to be soluble in ethanol (DHH, personal communication).
Therefore, 0.6 mg of Sulfoxide 1 was dissolved in 1.0 ml of 95%
ethanol. Distilled water was added until a precipitate began to form.
The final percent of ethanol was calculated to be 62.5%, and, the
Sulfoxide 1 concentration was calculated to be 0.395 ug/ul. This
solution was used in a cytotoxicity assay against P388 cells (Figure
1). The results indicated that 62.5% ethanol (v/v), alone, exhibited
as much cytotoxicity as Sulfoxide 1, dissolved in 62.5% ethanol.
Therefore, this was not the solvent of choice for further cell culture
assays.
Sulfoxide 1 was found to be completely soluble in 100% DMSO. The
cytotoxicity of DMSO against P388 cells in culture was then determined
(Figure 2). Results indicated 94% cell viability using 5% (v/v) DMSO,
and H80% viability using 6% DMSO. Subsequent in vitro experiments
using Sulfoxide 1 dissolved in DMSO included DMSO-only controls in
order to monitor solvent cytotoxicity. Because only very low doses of
100% DMSO can be injected into mice (2), other suitable solvents were
sought for in vivo experiments.
Attempts were made to solubilize Sulfoxide 1 by dissolving the
compound in 95% ethanol, evaporating the ethanol under N2 gas, and
then adding 1 ml of a solution of 5% BSA dissolved in PBS. This was
not successful. Use of 1 ml of Fatty Acid Free BSA gave the same
results.
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Attempts were also made to dilute solutions of Sulfoxide 1 in
DMSO with PBS. A 1% (v/v) solution of DMSO in PBS was possible if the
concentration of Sulfoxide 1 was sufficiently low (less than 0.01
Ug/Ul). However, due to the volume constraints posed by animal
injections, more concentrated solutions of Sulfoxide 1 were required.
Final concentrations of 20% and 50% DMSO in PBS were insufficient to
keep the Sulfoxide 1 in solution.
Liposome Dpi iverv .Svstpm
Attempts were also made with some success to encapsulate
Sulfoxide 1 in liposomes. Liposomes were prepared by dissolving 0.1
to 0.3 mg of Sulfoxide 1 and 50 ul each of PC and PS in 1 ml of CHC1 3
(in which Sulfoxide 1 was very soluble), then evaporating under N2
gas. The dry residue was rehydrated in 1 ml of PBS for 10 min at 25
°C The test tube was then heated to 60 °C in a water bath and
immediately vortexed for 1 min. After centrifugation at 14,000 x g
for 10 min in a Sorvall RC2B centrifuge, the liposomes were
resuspended in 1 ml of PBS and used immediately. The resuspended
liposomes appeared as a white solution, but as no precipitate formed
upon standing, the method was presumed successful.
It is apparent that solubility is a major consideration during
all phases of compound screening. When compounds are not water
soluble, organic solvents of an innocuous nature must be used. The
results of testing indicate that Sulfoxide 1 was ineffective in
ethanol solution, but much more cytotoxic when dissolved in DMSO.
DMSO is known for its ability to penetrate membranes (2); it appears
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that Sulfoxide 1 was able to enter the cell when dissolved in DMSO,
but not when dissolved in ethanol.
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Animal Tumor Model Systems
After the efficacy of the compound was determined in vitro the
next step was to determine the effectiveness of the compound in vivo
against a panel of different tumors. Further testing was done to
determine the toxicity of the compound in animal models.
Sulfoxide 1 was tested in mice in order to determine the LD50 ,
the toxicity to internal organs, and effectiveness against an
implanted L1210 lymphoma.
Materials and Methods
Animals, Rd/le, C3H/HeN, and DBA/2 mice were originally obtained
from Jackson Laboratories, and subsequently propagated in-house. Six
to eight week old mice of both sexes were used in experiments unless
otherwise stated.
Reagents, Sulfoxide 1 was prepared as previously described by
Dr. D. H. Hua. Suspensions of Sulfoxide 1 and liposomes were prepared
as under the section on "Solubilization".
Cell cultures, L1210 cells were originally obtained from the
American Type Culture Collection (ATCC) and subsequently propagated
in-house by culturing in Roswell Park Memorial Institute (RPMI) 1640
media supplemented with 10% Fetal Calf Serum (FCS).
Results and Discussion
In the first experiment, six C3H/HeN mice were injected
intraperitoneal^ (i.p.) with 0.1, 0.5, or 1 ml of either 1 mg/ml BSA
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in PBS or 6% DMSO (v/v) in PBS. The same mice were reinjected one
week later with the same volume of either 5 mg/ml BSA or 10% DMSO.
Mice were reinjected 3 days later with 5% BSA or 50% DMSO. Only one
death occurred: that of the mouse injected with 1 ml of 50% DMSO.
From this it was concluded that 5% BSA and up to 0.5 ml of 50% DMSO
would be suitable carriers for injecting Sulfoxide 1 into mice.
In the second experiment, the remaining mice from trial 1 were
injected i.p. with Sulfoxide 1 via one of the following: 1 ml of 1%
DMSO (8 ug Sulfoxide 1); 0.75 ml of 5% BSA (H30 ug Sulfoxide 1); 0.5
ml of 20% DMSO (80 ug Sulfoxide 1); or 1 ml of 20% DMSO (160 ug
Sulfoxide 1). No deaths occurred, and it was concluded that the LD50
range of Sulfoxide 1 had not yet been reached. Thus, Sulfoxide 1 does
not appear to be highly toxic when administered in vivo
.
In the third experiment, 4 week, old rd/le mice were injected,
i.p., with volumes ranging from 0.1 to 0.35 ml of 50% DMSO containing
125 to 525 ug of Sulfoxide 1. However, these were suspensions; the
volume of DMSO, constrained by the results of trial 1, was not enough
to hold the higher amounts of Sulfoxide 1 in solution. One death
occurred: that of the mouse injected with 525 ug of Sulfoxide 1 in
0.35 ml of 50% DMSO. The mouse injected with the next highest amount
of Sulfoxide 1, 375 ug in 0.25 ml, survived. Thus, it was concluded
that the range of concentration for LD50 determination had been found
and was between 375 and 525 ug Sulfoxide 1.
For the next experiment, C3H/HeN mice of both sexes were weighed
and divided into six groups of 4 mice each and one group of 7 mice.
The groups of 4 mice were injected with 400, 450, 475, 500, 525, and
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575 ug of Sulfoxide 1 in a suspension of 50% DMSO. The group of 7
mice was injected with a corresponding volume of 50% DMSO. Twentyfour
hours later, only 2 deaths had occurred: one mouse (weight 15.0 g)
which had been injected with 450 ug Sulfoxide 1 (30 mg/kg); and one
mouse (weight 20.6 g) which had been injected with 0.5 ml of 50% DMSO.
These deaths may have occurred from an internal organ being pierced by
the needle at the time of i.p. injection. Five days after injection,
one animal from each group was sacrificed and examined for gross
pathological defects (see below). The remaining animals in the groups
previously injected with 400-475 ug were divided into 2 groups and
injected with 600 or 650 ug Sulfoxide 1 as above. No deaths occurred
after these injections. The injection of 650 ug of Sulfoxide 1 into a
mouse weighing 15.2 g corresponds to an injection of 42.7 mg/kg.
Although an LD50 was not determined, an injection of 42.7 mg/kg was
deemed sufficient for declaring Sulfoxide 1 relatively nontoxic to
mice.
Thirty days after injection, all mice were sacrificed and
examined for gross pathological defects. It was found that 19 of 24
mice had liver necrosis; 7 of 24 had intestinal necrosis; 4 had
necrosis at the site of injection; and 1 had a granulomatous sac
typical of Type IV hypersensitivity (3). Of the eight mice which had
been injected twice, 4 had necrosis on the diaphragm in addition to
the liver necrosis, and had slightly enlarged livers. In contrast,
those mice which had been injected with 50% DMSO had no observable
necrosis or other changes. These results indicate that the liver is
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affected by Sulfoxide 1, probably due to the metabolic clearance of
the compound by the liver.
In order to determine the efficacy of Sulfoxide 1 against
implanted tumors, male and female DBA/2 mice were weighed and divided
into three groups of 4 and one group of 2, before i.p. injection with
1 x 10 L1210 cells. One group received i.p. injections of 0.1 mg of
Sulfoxide 1 in 50% DMSO on days 1 and 7, one group on days 3 and 10,
and one group on days 6 and 13 after tumor implantation. The control
group received only tumor cells. Mice were analyzed for weight gain,
tumor growth, and survival time. There was no increase in life span
(ILS) for any of the mice that received Sulfoxide 1.
In the next experiment, two groups of 2 DBA/2 mice were injected,
i.p., with 1 x 10 5 L1210 cells. Sulfoxide 1 was injected directly into
the tumor on the first day of nodule detection, and on days 3 and 8
following the first injection. Again there was no increase in life
span. It was concluded that Sulfoxide 1 could not overcome the tumor
burden if injections were delayed until the tumor was detectable by
palpation.
In the third experiment, two groups of mice were i.p. injected
with L1210 cells as before. The test group received i.p. injections
of 0.1 mg of Sulfoxide 1 in 0.1 ml of 50% DMSO on days 3 and 6 after
L1210 implantation. There was no increase in life span; on the
contrary, 2 of 4 test group mice died 2 days before 1 of 3 control
group mice died.
At this time it was clear that Sulfoxide 1 was not cytotoxic
against L1210 cells in vivo in our system. It was thought that the
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delivery system, a suspension of Sulfoxide 1 in 50% DMSO, was
inadequate. An in vitro experiment confirmed this suspicion. Wells
containing 1.5 x 10 5 L1210 cells and 0, 1, 2, 4, or 6 ug of Sulfoxide
1 as a 1 ug/ul suspension in 50% DMSO were incubated for 6 and 24
hours before determining cell number and viability using trypan blue
dye exclusion. All viabilities were above 90%. In contrast, cells
which had been exposed to 6 ug of Sulfoxide 1 in 100% DMSO typically
showed H70% viability after 6 hours, and 38% viability after 24 hours.
It was concluded that suspensions of Sulfoxide 1 in 50% DMSO are not
cytotoxic either in vitro or in vivo, and that another drug delivery
method was needed in order to continue in vivo testing. It is
probable that the Sulfoxide 1 was unable to enter the cell as a solid
in suspension.
In the next experiment, two groups of DBA/2 mice were i.p.
injected with L1210 cells as before. One week later, the test group
of mice received a single 0.2 ml ,i.p., injection of liposomes (see
section on "Solubilization" for method of preparation) that were made
with 0.1 mg of Sulfoxide 1. There was only a 2 day increase in the
Mean Survival Time (MST) of the test group, which was not significant.
For the next experiment, the test group was i.p. injected with
0.1 ml of liposomes once weekly for three weeks, beginning 4 days
after tumor implantation. The MST of the test group increased 4 days
over that of the control group, but again, was not significant.
In the next experiment, liposomes were, again, i.p. injected into
the test group of mice. Beginning one week after tumor implantation,
injections were given daily for 5 days, followed by 2 days of no
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injections, then 5 more daily injections. The injections of 0.1 ml
were directly into the tumor, as before. There was no increase in
life span following this protocol. In fact, the tumors of test group
mice appeared to grow larger and faster than those of the control
group mice. This may have been due to the slow absorption of the
fluid in the daily injections.
In the final experiment, two groups of three DBA/2 mice were
injected with L1210 cells as before. The test group received once
weekly injections of 100 ug of Sulfoxide 1 in 0.1 ml of 100% DMSO,
beginning the day of tumor implantation. Once again, there was no
increase in life span.
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Equilibrium Dialysis
Sulfoxide 1 has been shown to inhibit the uptake of labelled
thymidine and uridine. It is suspected that Sulfoxide 1 covalently
bonds to nucleophiles from DNA and RNA. In order to determine whether
Sulfoxide 1 binds to DNA, a DNA-binding experiment using the technique
of equilibrium dialysis (A) was attempted.
Materials and Methods
Reagents, Sulfoxide 1 and PBS were prepared as previously
described. DMSO was from Burdick & Jackson Laboratories, and 1,4
dioxane was from Fisher Scientific. Calf thymus DNA (Sigma), 0.5
mg/ml, was dissolved overnight in a 10% DMSO in PBS solution.
Materials, Dialysis tubing was from Spectrapor, Molecular Weight
Cut-Off (MWCO) 6-8,000, and VWR Scientific, Inc., 24 8. Dialysis
cells of 1 ml capacity were from Technilab Instruments.
Results and Discussion
In order to follow the progress of an equilibrium dialysis
experiment, it is necessary to measure the concentrations of the
"bound" vs. "free" ligand very accurately. In order to determine
whether this was possible using Sulfoxide 1 as the ligand, the UV
spectra between 250 - 350 run of Sulfoxide 1, 0.1 mg/ml in 10% DMSO,
nd DNA in 10% DMSO were taken in a Shimadzu UV-120-02
Spectrophotometer (Figure 3). The results indicate that the Amax= 270
nm for Sulfoxide 1, and the Xmax= 260 nm for DNA. However, DNA does
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not absorb above 320 run, while Sulfoxide 1 had a measurable absorbance
through 350 nm. Thus it was concluded that it would be possible to
measure changes in Sulfoxide 1 concentration spectrophotometrically
below 320 nm.
A sample of Sulfoxide 1 in 10% DMSO was placed in one side of the
dialysis chamber, and the solvent, 10% DMSO in PBS, was placed in the
other. The membrane used was from a previously prepared sample, MW
cut-off 8,000, which had been preserved in sodium azide and rinsed
well in deionized water prior to use. After 24 hr, the absorbance on
either side of the membrane was measured between 300 - 330 nm. From
the results, it was concluded that 1) Sulfoxide 1 would pass through
the membrane; 2) the DMSO would not destroy the membrane; and 3) that
more than 24 hr. would be required to reach equilibrium.
A standard curve of Sulfoxide 1 was attempted. During the course
of diluting concentrated solutions for absorbance measurements,
suspensions resulted, which are very difficult to use as a measure of
concentration. At the time, it was thought that during the actual
experiment, the DNA would bind enough of the Sulfoxide 1 for the
remainder to be held in solution so that concentrations could be
measured. Spectrapor membranes (MWCO 6 - 8,000) were boiled in double
distilled water, cooled, and split to form a single layer. Pieces
were cut to fit the dialysis chambers. As soon as possible after
assembling the chamber with a membrane, both sides were filled with
the appropriate solution using 1 cc tuberculin syringes. Duplicate
cells were assembled with Sulfoxide 1 vs. DMSO/PBS in one cell
(control), and the same concentration of Sulfoxide 1 vs. DNA in
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DMSO/PBS in the other. Cells were agitated on an orbit shaker at room
temperature. After 96 hr., the absorbance on either side of the
membrane was measured in the control cell. Results indicated that
almost none of the compound passed through the membrane in the control
cell, but that some did pass through the membranes of the chambers
containing DNA. The sides of the chambers containing DNA were not
measured for absorbance, therefore it is unknown whether equilibrium
was reached in those cells. It is clear that equilibrium was not
attained in the control cells.
In an effort to speed up the equilibrium process, a membrane with
larger pore size was used in time trials. Dialysis tubing of pore
size 24 A was prepared in the following manner: After heating at 80 -
90 °C for 1 - 2 hr in 10 mM sodium bicarbonate and 1 mM EDTA, the
tubing was then heated at 80 - 90 °C for 1 -2 hr in double distilled
water. The tubing was allowed to soak at room temperature in fresh
double distilled water for several hours before being stored in a
solution of 50% ethanol in deionized water. The tubing was rinsed in
deionized water immediately before use, then, soaked for 4 -24 hr in
the buffer in which it would be used; in this case, 10% DMSO in PBS.
Chambers were assembled and filled as before, but with 1 ml only to
ensure consistent volumes. In order to determine whether DNA could
pass through the larger pore size, one cell contained DNA vs. solvent,
and the other cells contained 100 ug Sulfoxide 1 vs. solvent for
absorbance measurements at 24, 48, and 72 hr. The absorbance
measurements indicated that the DNA or the membrane was probably
contaminated with some small absorbing ion as there was a very slight
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absorbance of the solvent compared with the solvent containing DNA.
The Sulfoxide 1 containing cells never reached equilibrium; in fact,
the Sulfoxide 1 aggregated as a precipitate in the bottoms of the
chambers. The trial was repeated using half as much Sulfoxide 1, with
similar results. The trial was repeated a third time using 20% DMSO in
PBS as the solvent with similar results.
Solubility trials were made using 10% and 20% 1,4-dioxane in PBS;
however, the DNA was precipitated by this solvent.
It was concluded that a DNA-binding experiment using the
technique of equilibrium dialysis could not be performed due to the
constraints posed by the differing solubility needs: DNA requires a
high salt solution in order to minimize the charge effects on either
side of a membrane; Sulfoxide 1 requires an organic solvent such as
DMSO in order to remain in solution; and, equilibrium dialysis
requires solutions, not suspensions, in order to reach equilibrium.
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Optimal Conditions for Concanavalin A
Stimulation of Normal Mouse Splenocytes
Sulfoxide 1 has been shown to be effective against tumor cells in
vitro. In order to determine whether Sulfoxide 1 is more effective
against dividing vs. non-dividing cells, a population of cells was
chosen for testing which is capable of both states. Spleen cells are
made up of both T and B lymphocytes, which exist in a quiescent state
until stimulated by antigens. Lymphocytes may also be stimulated to
divide through the use of mitogens. The most commonly used mitogens
are plant lectins which bind specifically to certain sugar residues on
the glycoproteins found on cell surfaces(5). Mitogens are specific:
phytohemagglutinin (PHA), from the red kidney bean, and Concanavalin A
(Con A) from jack beans, stimulate only T cells, while pokeweed
mitogen (PWM) and Bacterial lipopolysaccharide (LPS) are specific for
B cells. Mitogenic effects are distributed over a Gaussian curve.
Therefore, optimal conditions with respect to mitogen concentration
and time of exposure for maximal stimulation must be determined prior
to use.
Materials and Methods
Reagents, Con A, Type III or IV, dissolved in RPMI 1640 media
and filter sterilized through a 0.22 urn Acrodisc filter (Gelman, Ann
Arbor, MI) was prepared fresh for each experiment, and kept on ice
until use. [Methyl-3H ]-thymidine (50 Ci/mmol) was from ICN
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Radiochemicals. Lysing solution contained 280 mM NH4CI in 30 mM
TrisCl, pH 7.4. PBS was prepared as previously described.
Animals, DBA/2 mice were originally from Jackson Laboratories,
and subsequently propagated in house.
Results and Discussion
Spleens were removed from 1 or 2 mice and the splenocytes
dispersed in cold PBS. Pelleted cells were lysed with 1 ml of lysing
solution for 3-4 min. at room temperature in order to remove red blood
cells. Cells were then washed 3X with media containing FCS.
In the first set of experiments, 5 x 10 5 spleen cells/ well were
plated into 96 well plates with 0, 5, 10, or 20 ug/ml Con A Type III
in 200 ul final volume. After 24 hours, spleen cells were counted for
cell number and viability using trypan blue dye exclusion. The second
experiment was set up in the same manner, except that cells were
counted after both 24 and 48 hours. It was concluded that this method
was not appropriate for determining maximal stimulation by Con A.
Consequently, in subsequent experiments cells were pulsed with 1 uCi
of tritiated thymidine, as thymidine incorporation provides a better
correlation of maximal stimulation to cellular mitotic activity.
In the first experiment, spleen cells were plated as above and
cultured with 0, 5, 10, 15, 20, or 30 ug/ml Con A for 24 hr, and
pulsed with labelled thymidine for the final 3 hours. Results
indicated only a slight gain in mitotic activity over control cells.
In the second experiment, splenocytes were exposed to 0, 5, 10,
or 20 ug/ml Con A for 24, 48, or 72 hours. Results (Table 1)
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indicated that 48 hours exposure to 20 ug/ml Con A afforded maximal
stimulation to spleen cells.
It was necessary to redetermine the optimal time and
concentration of Con A necessary for maximal lymphocyte stimulation.
By mistake, the wrong bottle of Con A was used, such that, in this
experiment, the more highly purified Con A Type IV was used rather
than the Type III used previously. Splenocytes were cultured with 0,
5, 10, 15, 20, or 30 ug/ml Con A and pulsed with labelled thymidine as
before. Results indicated that 48 hours exposure to 15 ug/ml was
optimal. The more highly purified Con A gave much greater stimulation
than the Type III Con A used previously. This was beneficial,
however, because a greater contrast in results was seen after the
cells had been exposed to varying amounts of Sulfoxide 1 (see Table 5,
Chapter II).
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Protein Assay
In order to determine the amount of protein present in a given
number of tumor cells, a protein assay using the Bradford method (6)
was performed using bovine serum albumin as a control.
Materials and Methods
Reagents, Bio-Rad Protein Assay Dye Reagent Concentrate was from
Bio Rad Laboratories, Richmond, CA. BSA was dissolved in distilled
water as a 1 mg/ml solution and used to generate a standard curve.
Cell Culture, P388 cells were originally obtained from the ATCC,
and subsequently propagated in house. Because cells are normally
cultured in RPMI 1640 media supplemented with 10% FCS, it was
necessary to wash the cells several times with PBS to remove all
traces of serum proteins.
Results and Discussion
Replicate assays were run on samples containing 1 x 10 5 cells, 2
x 10 5 cells, and 1 x 10 6 cells. Briefly, 0.8 ml of sample was mixed
with 0.2 ml of the dye reagent, and the absorbance of the resulting
solution was measured on a Shimadzu UV-120-02 spectrophotometer at 595
nm.
From the standard curve generated, 1 x 10 5 cells contain 3.75 -
4.5 ug protein, 2 x 10 5 cells contain 6 - 8.75 ug protein, and 1 x 10 6
cells contain 30.5 - 33.5 ug protein. Because it is difficult to
control the exact number of cells in a sample, these ranges reflect
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not only the differing amounts of protein in a given number of cells
but also the differing numbers of cells in the sample.
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SUMMARY
This chapter has described experiments designed to determine the
activity of Sulfoxide 1 both as a toxic substance and as an antitumor
agent in vivo, and as a DNA-binding compound. In addition, the
results of preliminary experiments necessary for further work
including the solubilization of Sulfoxide 1, optimal conditions for
Con A stimulation of splenocytes, and a protein assay on tumor cells,
have been described.
In summary, the results in this chapter have shown:
a) Sulfoxide 1 is soluble in the organic solvents chloroform and
DMSO, slightly soluble in ethanol , and insoluble in aqueous solution.
BSA, as a carrier system, was unsuccessful. Liposome encapsulation
appeared to be successful as a solubilizing system.
b) Suspensions of Sulfoxide 1 are not cytotoxic either in vitro or in
vivo.
c) Sulfoxide 1 is not toxic in mice when injected i.p. up to 42.5
mg/kg.
d) Liver necrosis appears to be the major observable toxicity of
Sulfoxide 1.
e) In vivo, Sulfoxide 1 was ineffective against our system of
implanted L1210 leukemia.
f) Sulfoxide 1 has an absorbance spectrum between 250 -350 nm, past
the point of absorbance by DNA.
g) DNA binding by equilibrium dialysis cannot be measured until a
better solvent system is defined.
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h) The optimal conditions for Con A stimulation of splenocytes is 48
hours at 20 ug/ml (Type III), and 48 hours at 15 ug/ml (Type IV).
i) P388 tumor cells contain the following amounts of protein: 1 x
105cells, 3.75 - 4.5 ug protein; 2 x 10 5 cells, 6 - 8.75 ug protein;
and 1 x 10 6 cells, 30.5-33.5 ug protein.
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Fig. 1. Sulfoxide 1 Cytotoxicity Assay. P388 cells were exposed to
Sulfoxide 1 (0.395 ug/ul) dissolved in 62.5% ethanol (-•-) and to
62.5% ethanol alone (-o-) for 24 hours.
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Fig. 2. DMSO Cytotoxicity Assay. P388 cells were exposed to 1,5, 10,
and 20% DMSO for 24 hours.
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Fig. 3. Absorbance Spectra of Sulfoxide 1 and DNA. The absorbance
spectra of Sulfoxide 1, 0.1 mg/ml in 10% DMSO in PBS, (-o-) , and calf
thymus DNA, 0.5 mg/ml in 10% DMSO in PBS, (-•-), were measured between
250 - 350 nm.
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IV.
General Discussion
The search for new and improved drugs to better treat a variety
of cancers has led scientists to screen plants, marine animals,
microbial fermentation broths, and synthetic compounds. After
ensuring that the active agent has a novel structure, agents from
those sources which exhibit cytotoxicity in vitro are further screened
for activity in vivo against a variety of tumors. The most promising
compounds proceed through the screening process, until, finally, new
drugs are licensed for clinical use (1).
It is not enough to know only that a drug is cytotoxic to tumor
cells. The mechanism of action of a drug, as well as its demonstrated
activities against a variety of tumors on the tumor panel, can help
determine the most efficacious use of a drug in the treatment of
cancer. In addition, possible side effects and dose-limiting
toxicities are important to consider in designing chemotherapy
programs. For example, the combination of both myelosuppressive and
nonmyelosuppressive agents in multi-drug regimens helps to prevent the
total annihilation of bone marrow progenitor cells while maintaining
cytotoxic activity against the cancer (2).
The synthetic compound, 1-pheny 1-3-pheny lamino-4- ( p-
toluenesulfinyl)trans-l,5-hexadiene (Sulfoxide 1), was determined to
be cytotoxic to P388 and L1210 murine leukemia cells in vitro. In
order to determine the mechanism of this inhibition, synthesis
inhibition studies using radiolabeled precursors were performed.
Results indicated that both DNA and RNA synthesis were inhibited by
Sulfoxide 1. Further work involving the time course of this
inhibition suggested that both DNA and RNA synthesis were inhibited to
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about the same degree after one hour of exposure to Sulfoxide 1.
Because RNA is synthesized during the Gl phase of the cell cycle, and
DNA during S phase, it would appear that Sulfoxide 1 is a phase and
cycle nonspecific agent. Some of the alkylating agents, also phase
and cycle nonspecific agents, are more active in a particular phase
even though they are active in all phases (3). This may also be true
of Sulfoxide 1. Further work using synchronized cells is indicated.
In order to determine the cytotoxicity of Sulfoxide 1 for
non-cancerous cells, assays using normal murine splenocytes were
performed. Cell viability, as measured by trypan blue dye exclusion,
was determined for splenocytes which were stimulated or nonstimulated
by the mitogen Con A. Cell viability of P388 tumor cells was
determined for comparison. Results indicated that Sulfoxide 1 was
preferentially cytotoxic to the tumor cells. Because the membrane
composition of tumor cells is likely to be different from that of
spleen cells, thus allowing differential uptake of trypan blue dye,
another assay was performed using a different criterion of cell
viability: the incorporation of tritiated thymidine. The results
from this assay were quite different, as they indicated that Sulfoxide
1 was cytotoxic not only to tumor cells, but also to rapidly dividing
(Con A- stimulated) spleen cells. This suggested that Sulfoxide 1 is
toxic to proliferating cells, and also suggests that Sulfoxide 1 may
have similar side effects as the other known anticancer drugs which
are preferentially cytotoxic to proliferating cells: nausea, due to
intestinal tract toxicity; alopecia (hair loss); and, myelosuppression
(3). Again, further work is indicated to determine the side effects
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of Sulfoxide 1. This is usually part of Phase I clinical trials, if
the drug progresses to that point in screening.
After the cytotoxicity of Sulfoxide 1 for tumor cells in vitro
was demonstrated, it was then necessary to determine its toxicity in
vivo. However, due to the known toxicity of 100% DMSO to mice (4),
attempts were made to limit the amount of DMSO injected by using 50%
DMSO in buffered saline solutions. However, due to the nature of the
interaction between DMSO and water, such that water preferentially
hydrogen-bonds to DMSO (A), the solvating ability was lost, and
Sulfoxide 1 precipitated out of solution. In addition, heat is
generated upon mixing DMSO with water, and this may also have
adversely affected the Sulfoxide 1. Suspensions of Sulfoxide 1 were
injected, i.p., into mice, up to a calculated dose of 42.7 mg/kg body
weight, with no significant deaths. Internal examination for gross
pathological defects revealed liver necrosis as a major toxicity;
however, again, other experiments are necessary to determine Sulfoxide
1 toxicity to bone marrow and other organs.
The in vivo activity of Sulfoxide 1 against implanted L1210 cells
was then determined. Fifty percent suspensions of Sulfoxide 1 were
used in a variety of injection schedules, with no success. It was
possible that the tumor burden was already too great by the time of
the first injection, or that the tumor had already metastasized. It
was previously found that 2 to 4 days after implantation, P388 cells
leave the peritoneal cavity (5). Alternatively, it is very likely
that Sulfoxide 1
,
as a suspension, was not able to be taken up across
the membrane into the tumor cell, thus, no cytotoxicity was observed.
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An anomaly exists: a solution of Sulfoxide 1 in DMSO is added
directly to aqueous media for in vitro assays, and no precipitation
occurs, but cytotoxic activity is seen; a solution of Sulfoxide 1 in
DMSO is added to aqueous solvent before being added to an assay,
precipitation occurs, and no cytotoxic activity is seen.
In an attempt to increase the solubility/activity of Sulfoxide 1
in vivo, liposome encapsulation was tried. The method of liposome
preparation seemed to be successful as long as sufficient quantities
of lipid were present (to prevent the formation of a wax-like scum).
Again, a variety of injection schedules of Sulfoxide 1/liposomes was
tried, with no success. Perhaps an ineffective combination of lipids
was used: lipid composition of liposomes has been shown to be
important in drug delivery (6). Alternatively, the liposome may have
been internalized by the tumor cell, but Sulfoxide 1 was trapped in
the lysosome and was destroyed before it was able to exert its effect
(7). During the preparation of the liposomes, it was necessary to
heat to 60 °C for 1 minute. This temperature may have been
deleterious to Sulfoxide 1, and may have helped to decompose the
compound before it was injected. It is also possible that the
ineffectiveness of Sulfoxide 1 in vivo is a result of the inherent
differences between tissue culture systems and living animals. It is
possible that Sulfoxide 1 is cleaved or inactivated by an enzyme,
metabolized by the liver, or otherwise removed from the system before
the compound has time to exert its effects. If this possibility is
determined to be true, synthetic organic chemistry may be of value in
preparing an analog which is not easily cleaved or inactivated, and
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which shows activity in vivo. Finally, perhaps Sulfoxide 1 is not
active against L1210 in vivo, but is active against other tumor
systems. The illudins, for example, are not very effective against
murine tumors, but show activity against human tumors (8). Further
work on a variety of tumors is being conducted by the NCI.
It is not known how Sulfoxide 1 works. It is assumed that it
must enter the cell to be effective; Sulfoxide 1 was not cytotoxic
when dissolved in either ethanol or 50% DMSO in PBS. Dissolved in
100% DMSO, Sulfoxide 1 was very cytotoxic in vitro. As mentioned
previously, it is not known why Sulfoxide 1 does not precipitate out
when the DMSO solution mixes with the media in an in vitro assay. The
insolubility of Sulfoxide 1 in water suggests that the compound is
hydrophobic, and, as such, may be lipid soluble. Some of the
compound's cytotoxicity may be due to membrane effects, as in the case
of doxorubicin (9). Further work using radiolabeled Sulfoxide 1 may
help determine whether the drug actually enters the cell, and how it
is distributed within the cell.
It is thought that Sulfoxide 1 must be activated to be cytotoxic.
The activation may occur in the following manner: In solution, the
phenylamine of Sulfoxide 1 attracts an H+ ion, which results in a
positive charge on the nitrogen (see Figure 5). As aniline is a good
leaving group, the positive charge is transferred to carbon-3. The
aniline extracts the hydrogen from carbon-4, and a double bond between
carbons 3 and 4 is formed, thus giving rise to a conjugated triene.
This triene is then subject to attack by such nucleophiles as a
guanine N 7 from DNA or RNA, or sulfhydryl from protein, thus giving
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rise to an alkylation. Should another addition occur, crosslinks may
be formed. The aniline itself may contribute to the cytotoxic effects
of Sulfoxide 1. The question remains of how the triene reaches the
DNA and RNA to exert these effects. One possibility is the following.
It is known that DMSO is able to transport certain drugs as it moves.
It is also known that DMSO passes through membranes by exchanging
sites with bound water molecules. Inside the cell, proteins, nucleic
acids, and polysaccharides are bonded together and covered by an
"ice-like" sheath of water (10). As the DMSO comes into contact with
these structures, the transported Sulfoxide 1 may then be able to
exert its effects on the exposed portions of the proteins or nucleic
acids. In this manner, the Sulfoxide 1 is protected from
precipitation by the DMSO, and is delivered directly to the sites of
action.
In conclusion, the synthetic compound Sulfoxide 1 is a cytotoxic
compound which reacts in the same manner as an alkylating agent.
Although cytotoxicity could only be demonstrated in vitro, with an
improved solvent system or drug delivery system, Sulfoxide 1 could
prove to be an effective new drug in the treatment of cancer.
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Fig. 1. Proposed Mechanism of Action of Sulfoxide 1. Sulfoxide 1
forms a triene in solution which is subject to nucleophilic attack by
guanine N? of DNA or RNA. Mono- or bifunctional alkylations may
occur.
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ABSTRACT
The synthetic compound, 1-pheny 1-3-pheny lamino-4- ( p-
toluenesulfinyl) trans- 1 ,5-hexadiene (Sulfoxide 1), is an intermediate
in the synthesis of an antibiotic carbapenum. Its novel structure is
unlike other known anticancer agents. The compound exhibits in vitro
cytotoxic activity against P388 (LD50= 30 ug/ml) and L1210 (LD50= 29
Ug/ml) murine leukemia cells in culture. This cytotoxicity compares
favorably with the activity of known anticancer drugs such as
doxorubicin.
Cytotoxicity assays against normal mouse splenocytes suggest that
Sulfoxide 1 is preferentially cytotoxic to proliferating cells. Both
P388 tumor cells and mitogen-stimulated splenocytes showed greatly
reduced cell viability after 24 hours of exposure to Sulfoxide 1. In
contrast, normal mouse splenocytes were not significantly effected.
Toxicity studies in animal models suggest that Sulfoxide 1 is not
overly toxic in vivo. The drug was not lethal at doses less than or
equal to 42.7 mg/kg body weight when injected into mice, although
liver necrosis was the major observable toxicity.
Studies of Sulfoxide 1 effectiveness against tumor-bearing mice
suggest that Sulfoxide 1 is either inactive or inactivated in vivo,
such that no cytotoxic activity is seen against implanted L1210 tumor
cells. Neither drug suspensions nor liposome-encapsulation of the
drug caused an increase in life span of treated mice over control
mice,
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Synthesis inhibition studies using radiolabeled precursors
demonstrate that both DNA and RNA synthesis are inhibited by Sulfoxide
1 within one hour of exposure to the drug. This suggests that
Sulfoxide 1 is a phase- and cycle-nonspecific agent, similar to the
alkylating agents. There was no inhibition of protein synthesis
following three hours of drug exposure.
Structure analysis suggests that Sulfoxide 1 is capable of
reacting as either a mono- or bifunctional alkylating agent, similar
to Mitomycin C. This mechanism of action is supported by the observed
effects of this novel anticancer drug.
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